

Children's Mercy Kansas City

SHARE @ Children's Mercy

Clinical Critically Appraised Topics

Critically Appraised Topics

4-2023

Bronchiolitis: Hypertonic Saline

Children's Mercy Kansas City

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/clinical-critically-appraised-topics>



Part of the Pediatrics Commons

Specific Care Question

For hospitalized children \leq 24 months of age with bronchiolitis, does use of nebulized 3% hypertonic saline (HS) impact patient outcomes?

Recommendations from the Bronchiolitis CPG Committee Based on Current Literature (Best Evidence) Only

A conditional recommendation is made against use of nebulized 3% HS, based on the GRADE Evidence to Decision instrument^a the Summary of Findings Table^a. The overall certainty in the evidence is very low^a. Eleven randomized control trials showed a shorter length of stay for patients receiving treatment with HS, MD = -6.47 hours, 95% CI [-12.72, -0.22], $p = .04$. There was no difference in the need for oxygen supplementation, duration of oxygen supplementation, or improvement of clinical severity scores for patients receiving treatment with HS when compared to no treatment with HS. The potential for shorter length of stay was balanced against the associated costs (monetary and otherwise). See Summary by Outcome for substantiation of recommendations.

Recommendations from the Bronchiolitis CPG Committee

Following a review of additional considerations using the GRADE Evidence to Decision instrument^a (see Appendix), a conditional recommendation is made against use of nebulized 3% HS based on evidence showing the limited benefits of treatment are outweighed by the cost of treatment and burden on hospital staff. Additional considerations should be taken for patients with history of prematurity or comorbidities for whom HS may be of higher value.

Literature Summary

Background

Bronchiolitis is a common illness in patients less than 2 years of age and is one of the most frequent causes of hospital admission for patients less than 12 months of age (Ralston et al., 2014). Patients with bronchiolitis experience mucus production caused by inflammation of the bronchioles, which may result in mucus plugging. Nebulized 3% hypertonic saline (HS) is used to improve mucociliary clearance, though there is no direct evidence to show significant improvement of patient outcomes (Ralston et al., 2010). The most recent AAP guideline makes a weak recommendation for HS use in the inpatient setting for patients whose admission exceeds 3 days, however, the average admission for bronchiolitis in the U.S. is 2.4 days (Ralston et al., 2014). This recommendation is based on evidence published prior to 2014. The search dates were determined based on the publication date of the current AAP guideline (Ralston et al., 2014) and one year previous to publication was selected to include studies that may not have been identified otherwise. This review will summarize identified literature to answer the specific care question.

Study characteristics. The search for suitable studies was completed on January 26, 2023. Jeremy Beyer, MD and Shautonja Woods, BS, RRT-NPS reviewed the 53 titles and/or abstracts found in the search and identified^b 20 single studies, one systematic review, and three meta-analyses believed to answer the question. After an in-depth review of the single studies^b, 10 studies answered the question. After an in-depth review of the systematic review and four meta-analyses^b, five single studies met the timeframe criteria designated in the original search strategy and answered the question.

Race/Ethnicity

Race and ethnicity as defined by the individual authors were reviewed in the literature. Of the studies that reported on race and ethnicity, 11-35% of participants were Black and 63-71% were Hispanic.

Question Answered. For hospitalized children \leq 24 months of age with bronchiolitis does use of nebulized 3% hypertonic saline (HS) impact patient outcomes?

Alatwani et al. (2021) completed a randomized control trial (RCT) comparing hospitalized patients up to 18 months of age with moderate or severe bronchiolitis ($N = 159$). Patients were randomized to receive either 4 mL of 3% HS via nebulizer upon admission and then every 6 hours ($n = 83$) or conventional treatment as ordered by a physician ($n = 76$).

Everard et al. (2014) completed an RCT comparing patients less than 12 months of age hospitalized with acute bronchiolitis ($N = 317$). All patients received standard supportive care (oxygen as required and fluid administration as appropriate). Patients were randomized to receive either treatment with 4 mL nebulized 3% HS every 6 hours in addition to standard care (oxygen and fluids as needed) ($n = 158$) or standard care without nebulized HS ($n = 159$).

Flores-González et al. (2019) completed an RCT comparing patients less than 12 months of age hospitalized with acute bronchiolitis ($N = 68$). Following the initial treatment with deep nasal suctioning of 0.9% nasal saline drops and nebulization of 1.25 mg salbutamol in 3 mL of 0.9% normal saline (NS), patients were randomized to receive treatment every 6 hours with either 3 mL of nebulized 3% HS with 1.25 mg salbutamol ($n = 33$) or 3 mL of nebulized NS with 1.25 mg salbutamol.

Hmar et al. (2021) completed an RCT comparing patients aged 3 months to 2 years hospitalized with acute bronchiolitis ($N = 158$). Patients were randomized to receive treatment every 6 hours with either 3 mL of nebulized 3% HS with salbutamol or nebulized 3 mL of NS with salbutamol.

Islam et al. (2018) completed an RCT comparing patients 1 month to 2 years of age hospitalized with symptoms of bronchiolitis ($N = 90$). Patients were randomized to receive treatment every 8 hours with either 4 mL nebulized 3% HS ($n = 45$) or 4 mL nebulized NS ($n = 45$).

Jaquet-Pilloud et al. (2020) completed an RCT comparing patients aged 6 weeks to 2 years of age hospitalized with acute bronchiolitis ($N = 120$). All patients received standard supportive care (nasal suctioning, fluids, and supplemental oxygen as needed). Patients were randomized to receive either 4 mL of nebulized 3% HS every 6 hours ($n = 61$) or standard care without nebulized saline ($n = 59$).

Köse et al. (2016) completed an RCT comparing patients aged 1 to 24 months hospitalized with bronchiolitis ($N = 104$). Patients were randomized to receive either treatment twice upon admission at 30 minute intervals and then every 6 hours with either 2.5 mL nebulized NS with 0.15 mg salbutamol ($n = 34$), 2.5 mL nebulized 3% HS with 0.15 mg salbutamol ($n = 35$), or 2.5 mL nebulized 7% HS with 0.15 mg salbutamol ($n = 35$).

Mahesh Kumar et al. (2013) completed an RCT comparing patients less than 2 years of age hospitalized with a lower respiratory tract infection ($N = 40$). Patients were randomized to receive treatment every 6 hours with either 3 mL nebulized 3% HS with 0.15 mg salbutamol ($n = 20$) or 3 mL nebulized NS with 0.15 mg salbutamol ($n = 20$).

Morikawa et al. (2018) completed an RCT comparing patients less than 12 months of age hospitalized with acute bronchiolitis due to respiratory syncytial virus (RSV) ($N = 128$). All patients received oxygen supplementation, bronchodilators, intravenous fluids, deep nasal suction, and antibiotics as needed at the discretion of the attending physicians. Patients were randomized to receive treatment six times daily with either 2 mL nebulized 3% HS with 0.1 mL of 0.5% salbutamol ($n = 63$) or 2 mL nebulized NS with 0.1 mL 0.5% salbutamol ($n = 65$).

Ojha et al. (2014) completed an RCT comparing patients between 6 weeks and 24 months of age hospitalized with bronchiolitis ($N = 72$). All patients received supplemental oxygen as needed. Patients were randomized to receive treatment every 8 hours (or more often at the discretion of the physician) with either 4 mL of nebulized 3% hypertonic saline ($n = 36$) or 4 mL nebulized 0.9% saline ($n = 36$).

Pandit et al. (2013) completed an RCT comparing patients aged 2 to 12 months hospitalized with acute bronchiolitis ($N = 100$). Patients were randomized to receive treatment with either 4 mL of nebulized 3% hypertonic saline with 1 mL of 1:1,000 adrenaline ($n = 51$) or 4 mL nebulized 0.9% saline with 1 mL of 1:1,000 adrenaline ($n = 49$). Patients initially received three treatments over the first 3 hours after admission, then received treatment every 6 hours thereafter.

Sharma et al. (2013) completed an RCT comparing patients aged 1 to 24 months hospitalized with acute bronchiolitis ($N = 250$). Patients were randomized to receive treatment every 4 hours with either 4 mL nebulized 3% hypertonic saline with 2.5 mg salbutamol ($n = 125$) or 4 mL nebulized 0.9% saline with 2.5 mg salbutamol ($n = 123$).

Silver et al. (2015) completed an RCT comparing patients less than 12 months of age hospitalized with bronchiolitis ($N = 227$). Patients were randomized to receive treatment every 4 hours with either 4 mL of nebulized 3% hypertonic saline ($n = 113$) or 4 mL of nebulized 0.9% saline ($n = 114$). An additional two treatments could be administered every 24 hours at the discretion of the physician.

Teunissen et al. (2014) completed an RCT comparing patients 0 to 24 months of age hospitalized with mild to severe viral bronchiolitis ($N = 247$). All patients received oxygen supplementation as needed. Patients were randomized to receive treatment every 8 hours with either 4 mL nebulized 3% hypertonic saline with 2.5 mg salbutamol ($n = 97$), 4 mL nebulized 6% hypertonic saline with 2.5 mg salbutamol ($n = 102$), or 4 mL nebulized 0.9% saline with 2.5 mg salbutamol ($n = 93$).

Wu et al. (2014) completed an RCT comparing patients less than 24 months of age hospitalized with viral bronchiolitis ($N = 408$). Patients were randomized to receive treatment with either 4 mL nebulized 3% hypertonic saline with 2.5 mg albuterol sulfate ($n = 211$) or 4 mL nebulized 0.9% saline with 2.5 mg albuterol sulfate ($n = 197$). Patients may have received up to three treatments every 20 minutes in the emergency department, and once admitted, received treatments every 8 hours.

Data Summary by Outcome (rationale for evidence certainty rating^a provided for each outcome)

Length of Stay (LOS)

Eleven RCT studies (Everard, 2014; Flores-González, 2016; Hmar, 2021; Islam, 2018; Jaquet-Pilloud, 2019; Mahesh Kumar, 2013; Morikawa, 2018; Ojha, 2014; Pandit, 2013; Sharma, 2013; Wu, 2014) reported the mean (SD) LOS, ($n = 1,449$). For the outcome of LOS, the $MD = -6.47$ hours, 95% CI [-12.72, -0.22], $p = .04$, indicated the LOS was shorter for patients that received treatment with 3% HS versus no treatment with 3% HS (see Figure 2 & Table 1).

Certainty Of The Evidence For LOS. The certainty of the body of evidence was low. The body of evidence was found to not have serious inconsistency or imprecision, however, serious risk of bias and serious indirectness were found. Risk of bias was serious due to lack of blinding of study personnel. Indirectness was serious due to the variability of the control used in each study (normal saline versus standard care), addition of a beta agonist to the nebulized treatments, and variation in the frequency of administration of HS treatments.

LOS: Low risk of bias

A subgroup analysis was performed for the four studies with low risk of bias ($n = 431$) (see Figure 3 & Table 1). In the subgroup of the four studies with low risk of bias, there was no difference in LOS for patients treated with 3% HS compared to patients not treated with 3% HS, $MD = -7.17$, 95% CI [-20.40, 6.07], $p = 0.29$.

Certainty Of The Evidence For LOS: Low risk of bias. The certainty of the evidence was low. The body of evidence was found to not have serious risk of bias or inconsistency, however, serious indirectness and serious imprecision were found. Indirectness was serious due to the variability of the control used

in each study (normal saline versus standard care), addition of a beta agonist to the nebulized treatments, and variation in the frequency of administration of HS treatments. Imprecision was due to the low number of participants and the wide CI.

LOS: High risk of bias

A subgroup analysis was performed for the four studies with high or unclear risk of bias ($n = 1018$) (see Figure 3 & Table 1). In the subgroup of the seven studies with high or unclear risk of bias, there was no difference in LOS for patients treated with 3% HS compared to patients not treated with 3% HS $MD = -6.00$, 95% CI $[-13.49, 1.50]$, $p = 0.12$. The certainty of the evidence is very low.

Certainty Of The Evidence For LOS: High risk of bias. The certainty of the body of evidence was low. The body of evidence was found to not have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Risk of bias was serious due to the lack of blinding of study personnel. Indirectness was serious due to the variability of the control used in each study (normal saline versus standard care), addition of a beta agonist to the nebulized treatments, and variation in the frequency of administration of HS treatments. Imprecision was due to the wide CI.

LOS: HS versus standard care (SC)

A subgroup analysis was performed for the two studies ($N = 413$) that compared treatment with nebulized 3% HS versus standard care (no nebulized treatment) (see Figure 4 & Table 1). In the subgroup of the two studies that compared treatment with 3% HS versus standard care, there was no difference in LOS for patients that received treatment with 3% HS compared to patients that did not received treatment with 3% HS, $MD = -2.43$, 95% CI $[-13.41, 8.54]$, $p = .66$.

Certainty of the Evidence for LOS: HS versus SC. The certainty of the evidence was low. The body of evidence was found to not have serious inconsistency or indirectness, however, serious risk of bias and serious imprecision were found. Serious risk of bias was due to the lack of blinding of study personnel. Serious imprecision was due to the low number of participants and the wide CI.

LOS: HS versus NS

A subgroup analysis was performed for the nine studies that compared treatment with nebulized 3% HS versus treatment with nebulized NS ($N = 1036$) (see Figure 4 & Table 1). In the subgroup of the nine studies that compared treatment with 3% HS versus NS, there was no difference in LOS for patients that received treatment with 3% HS compared to patients that did not received treatment with 3% HS, $MD = -7.29$, 95% CI $[-14.78, 0.20]$, $p = .06$.

Certainty of the Evidence for LOS: HS versus NS. The certainty of the evidence was very low. The body of evidence was found to have serious risk of bias, serious inconsistency, serious indirectness, and serious imprecision. Serious risk of bias was due to the lack of blinding of study personnel. Serious inconsistency was due to unexplained heterogeneity. Serious indirectness was due to addition of a beta agonist to nebulized treatments and variation in the frequency of administration of HS treatments. Serious imprecision was due to the wide CI.

LOS: HS with a beta agonist or adrenaline

A subgroup analysis was performed for the seven studies that included a beta agonist or epinephrine with nebulized treatment ($N = 887$) (see Figure 5 & Table 1). In the subgroup of the two studies that included a beta agonist or adrenaline with nebulized treatment, there was no difference in LOS for patients treated with 3% HS compared to patients not treated with 3% HS, $MD = -6.86$, 95% CI $[-16.11, 2.40]$, $p = .15$.

Certainty of the Evidence for LOS: HS with a beta agonist or adrenaline. The certainty of the evidence was very low. The body of evidence was found to have serious risk of bias, serious inconsistency, serious indirectness, and serious imprecision. Serious risk of bias was due to the lack

of blinding of study personnel. Serious inconsistency was due to unexplained heterogeneity. Serious indirectness was due to the variation of use of a beta agonist or adrenaline. Serious imprecision was due to the low number of participants and the wide CI.

LOS: HS with no beta agonist or adrenaline

A subgroup analysis was performed for the four studies that did not include a beta agonist or epinephrine with nebulized treatment ($n = 562$) (see Figure 5 & Table 1). In the subgroup of the two studies that did not include a beta agonist or epinephrine with nebulized treatment, there was no difference in LOS for patients treated with 3% HS compared to patients not treated with 3% HS, $MD = -6.04$, 95% CI $[-15.19, 3.12]$, $p = .13$.

Certainty of the Evidence for LOS: HS with no beta agonist or adrenaline. The certainty of the evidence is very low. The body of evidence was found to not have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was due to the lack of blinding of study personnel. Serious indirectness was due to the variation of the frequency of administration of HS treatments. Serious imprecision was due to the low number of participants and the wide CI.

LOS: HS administered every 4 hours

A subgroup analysis was performed for the two studies that administered nebulized treatment with 3% HS every 4 hours ($N = 376$) (see Figure 6 & Table 1). In the subgroup of the two studies that administered treatment every 4 hours, there was no difference in LOS for patients treated with 3% HS compared to the patients not treated with 3% HS, $MD = 0.22$, 95% CI $[-5.22, 5.66]$, $p = .94$.

Certainty of the Evidence for LOS: HS administered every 4 hours. The certainty of the evidence was very low. The body of evidence was not found to have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was due to the lack of blinding of study personnel. Serious indirectness was due to the variation of use of a beta agonist or adrenaline. Serious imprecision was due to the low number of participants and the wide CI.

LOS: HS administered every 6 hours

A subgroup analysis was performed for the six studies that administered nebulized treatment with 3% HS every 6 hours ($N = 779$) (see Figure 6 & Table 1). In the subgroup of the six studies that administered treatment every 6 hours, there was no difference in LOS for patients treated with 3% HS compared to the patients not treated with 3% HS, $MD = -8.52$, 95% CI $[-17.23, 0.19]$, $p = .06$.

Certainty of the Evidence for LOS: HS administered every 6 hours. The certainty of the evidence is very low. The body of evidence was not found to have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was due to the lack of blinding of study personnel. Serious indirectness was due to the variation of use of a beta agonist or adrenaline. Serious imprecision was due to the low number of participants and the wide CI.

LOS: HS administered every 8 hours

A subgroup analysis was performed for the three studies that administered nebulized treatment with 3% HS every 8 hours ($N = 294$) (see Figure 6 & Table 1). In the subgroup of the three studies that administered treatment every 8 hours, there was no difference in LOS for patients treated with 3% HS compared to the patients not treated with 3% HS, $MD = -9.9$, 95% CI $[-23.49, 3.68]$, $p = .15$.

Certainty of the Evidence for LOS: HS administered every 8 hours. The certainty of the evidence is very low. The certainty of the evidence is very low. The body of evidence was not found to have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were

found. Serious risk of bias was due to the lack of blinding of study personnel. Serious indirectness was due to the variation of use of a beta agonist or adrenaline. Serious imprecision was due to the low number of participants and the wide CI.

LOS: Studies not included in meta-analysis

Alatwani et al. (2021) reported the mean LOS without SD and found a shorter LOS in the group that received treatment with HS (3.38 days) compared to the group that received treatment with nebulized NS (4.67 days), a reduction of 1.3 days (27.8%), $p = .001$.

Kose et al. (2016) reported the mean (min – max) LOS and found that the LOS was not different for the groups that received nebulized 3% HS (64 hours), NS (72 hours), or 7% HS (60 hours), $p = .76$.

Silver et al., (2015) found that the median (IQR) LOS in days was not different for the group that received nebulized 3% HS (2.1 (1.2 – 4.6)) compared to the group that received nebulized NS (2.1 (1.2 – 3.8)), $p = .73$.

Teunissen et al. (2014) reported the median (IQR) LOS in hours and did not find a difference between the group that received nebulized 3% HS (69 (57)), NS (53 (53)), and nebulized 6% HS (70 (69)), $p = .29$.

Certainty of the Evidence for LOS: Qualitative analysis. The certainty of the evidence was very low. The body of evidence was found to have serious risk of bias, serious indirectness, and serious imprecision. Serious risk of bias was found due to lack of blinding of study personnel. Serious indirectness was found due to use of beta-agonists and variation of frequency of nebulization. Serious imprecision was found due to a low number of participants. As results were unable to be pooled inconsistency was not assessed.

Need for Supplemental Oxygen

Four studies (Flores-González, 2016; Islam, 2018; Ojha, 2014; Teunissen, 2014) reported the need for supplemental oxygen ($n = 430$). For the outcome of need for supplemental oxygen, the $OR = 0.88$, 95% CI [0.57, 1.34], $p = .54$, indicating there was no difference between the intervention of treatment with nebulized 3% HS compared to the intervention of no treatment with nebulized 3% HS. (see Figure 10 & Table 1).

Certainty of the Evidence for Need for Supplemental Oxygen. The certainty of the body of evidence was very low. The body of evidence was found to not have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was due to lack of blinding of study personnel. Serious indirectness was due to the variation of hospitals' criteria for administration of supplemental oxygen and variation in the use of beta agonists or adrenaline. Serious imprecision was due to the low number of study participants.

Duration of Supplemental Oxygen

Five studies (Flores-González, 2016; Islam, 2018; Jaquet-Pilloud, 2019; Morikawa, 2018; Ojha, 2014) reported the duration of supplemental oxygen in hours ($n = 346$). For the outcome of duration of supplemental oxygen, the $MD = -5.84$, 95% CI [-11.41, -0.28], $p = <.05$, indicating the intervention of treatment with nebulized 3% HS was favorable to the intervention of no treatment with 3% HS.

Certainty of the Evidence for Duration of Supplemental Oxygen. The certainty of the body of evidence was very low. The body of evidence was found to not have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of blinding was due to the lack of blinding of study personnel. Serious indirectness was due to the variation of use of nebulized NS versus standard care as the control. Serious imprecision was due to the low number of study participants.

Clinical Severity Scores (CSS) Following 1 Day of Treatment

Three studies (Flores-González, 2016; Hmar, 2021; Kose, 2016) reported the mean (SD) CSS (as described by Wang et al., 1992) following 1 day of treatment ($n = 296$). For the outcome of improvement of CSS, the $MD = -0.76$, 95% CI $[-1.07, -.046]$, $p = <.05$, indicating the treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 7 & Table 1).

Certainty Of The Evidence For CSS Following 1 Day of Treatment. The certainty of the body of evidence was very low. The body of evidence was found to not have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was assessed to lack of blinding of study personnel. Serious indirectness was due to the variation in the ranges of CSS. Serious imprecision was due to a low number of study participants.

Clinical Severity Scores (CSS) Following 2 Days of Treatment

Two studies (Flores-González, 2016; Hmar, 2021) reported the mean (SD) CSS (as described by Wang et al., 1992) following 2 days of treatment ($n = 226$). For the outcome of improvement of CSS, the $MD = -0.54$, 95% CI $[-0.79, -.028]$, $p = <.05$, indicating the intervention of treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 8 & Table 1).

Certainty Of The Evidence For CSS Following 2 Days of Treatment. The certainty of the body of evidence was very low. The body of evidence was found not to have serious inconsistency, however, serious risk of bias, serious indirectness, and serious imprecision were found. Serious risk of bias was assessed due to lack of blinding of study personnel. Serious indirectness was due to the variation in the baseline CSS. Serious imprecision was due to a low number of study participants.

Clinical Severity Scores (CSS) Following 3 Days of Treatment

Two studies (Flores-González, 2016; Islam, 2018) reported the mean (SD) CSS (as described by Wang et al., 1992) following 3 days of treatment ($n = 296$). For the outcome of improvement of CSS, the $MD = -1.19$, 95% CI $[-1.67, -.071]$, $p = <.05$, indicating the treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 9 & Table 1).

Certainty Of The Evidence For CSS Following 3 Days of Treatment. The certainty of the body of evidence was very low. The body of evidence was found to not have serious risk of bias, however, serious inconsistency, serious indirectness, and serious imprecision were found. Serious inconsistency was assessed due to unexplained heterogeneity. Serious indirectness was due to the variation in the ranges of CSS. Serious imprecision was due to a low number of study participants.

Identification of Studies

Search Strategy and Results (see Figure 1)

- 1) 'bronchiolitis'/exp OR bronchiolitis:ti,ab,kw
- 2) inhaled:ti,ab,kw OR inhalation:ti,ab,kw OR nebulized:ti,ab,kw OR nebulize:ti,ab,kw OR 'metered dose inhaler'/exp OR 'inhalational drug administration'/exp OR 'nebulizer'/exp
- 3) 'hypertonic saline':ti,ab,kw
- 4) #2 AND #3
- 5) #1 AND #4
- 6) #1 AND #4 AND (2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py OR 2021:py OR 2022:py OR 2023:py) AND ([infant]/lim OR [newborn]/lim OR [preschool]/lim) AND ('article'/it OR 'article in press'/it) NOT ('case report'/de OR 'case study'/de OR 'human cell'/de)

Search Dates: 2013–Current.

Records identified through database searching $n = 53$

Additional records identified through other sources $n = 10$

Studies Included in this Review

Citation	Study Type
Alatwani et al. (2021)	RCT
Everard et al. (2014)	RCT
Flores et al. (2016)	RCT
Hmar et al. (2021)	RCT
Islam et al. (2018)	RCT
Jaquet-Pilloud et al. (2019)	RCT
Kose et al. (2016)	RCT
Mahesh Kumar et al. (2013)	RCT
Morikawa et al. (2018)	RCT
Ojha et al. (2014)	RCT
Pandit et al. (2013)	RCT
Sharma et al. (2013)	RCT
Silver et al. (2015)	RCT
Teunissen et al. (2014)	RCT
Wu et al. (2014)	RCT

Studies Not Included in this Review with Exclusion Rationale

Citation	Reason for exclusion
Angoulvant et al. (2017)	Does not include hospitalized patients
Brooks et al. (2016)	Meta-analysis including studies published prior to 2013
Canty & Colomb-Lippa (2014)	Narrative review
Everard et al. (2015)	Re-analysis of previous study
Faten et al. (2015)	Does not include intervention of 3% HS
Florin (2015)	Use of beta agonist in control patients only
Heikkilä et al. (2018)	Meta-analysis including interventions other than 3% HS
Jacobs et al. (2014)	Does not include intervention of 3% HS
Li & Zhao (2014)	Not available in English
Lin et al. (2022)	Not available in English
Liu & Li (2014)	Not available in English
Nenna & Costantino (2013)	Does not include intervention of 3% HS
Pandit et al. (2014)	Use of beta agonist in control patients only
Shahid et al. (2022)	Does not include hospitalized patients
Tinsa et al. (2014)	Does not include intervention of 3% HS
Wang (2014)	Not available in English

Yu et al. (2022)	Meta-analysis including studies published prior to 2013
Zhang et al. (2018)	Meta-analysis includes non-hospitalized patients

Methods Used for Appraisal and Synthesis

- ^aThe [GRADEpro Guideline Development Tool \(GDT\)](#) is the tool used to create the Summary of Findings (SOF) table(s) for this analysis. Using the GDT, the author of this CAT rates the certainty of the evidence based on four factors: *within-study risk of bias, consistency among studies, directness of evidence, and precision of effect estimates*. Each factor is subjectively judged against the author's confidence of the estimated treatment effect. Confidence is assessed as not serious, serious or very serious. If the attribute of serious or very serious is assessed, the author will provide an explanation.
- ^bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid, 2017).
- ^cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias and create the forest plots found in this analysis.
- ^dThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched, screened, and eligibility criteria is applied (Page et al., 2021).

References to Appraisal and Synthesis Methods

- ^aGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available from gradepro.org.
- ^bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. *Systematic Reviews*, 5(1), 210. doi:10.1186/s13643-016-0384-4
- ^cHiggins, J. P. T., & Green, S. e. (2011). *Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]* (Version 5.1.0 ed.): The Cochrane Collaboration, 2011.
- ^dPage, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *International journal of surgery*, 88, 105906. **For more information, visit www.prisma-statement.org.**

Question Originator

A. Nedved, MD
Findings from this review were presented with the question originator and S. Woods, BHS, RRT, J. Hartley, DO, and M. Collins, MD, MPH on April 24, 2023.

Medical Librarian Responsible for the Search Strategy

K. Swaggart, MLIS, AHIP

EBP Team or EBP Scholars Responsible for Analyzing the Literature

- T. Bontrager, MSN, RN, CPEN
- B. Carroll, MA, BSN, RN, IBCLC
- J. Cronin, RN, BSN, MBA, CCRC
- K. Foote, LSCSW, LCSW, OSW-C
- M. Gripka, MT (ASCP) SM
- K. Hess, PharmD
- J. Higgins, RN, MSN, CPNP

M. Orlick, MS, RD, CSP, LD
K. Ott, OTD, OTR/L
A. Randall, MHA, RRT, RRT-ACCS, RRT-NPS, C-NPT, CPPS
R. Rhodes, MHA, RRT, RRT-ACCS, RRT-NPS, C-NPT, CPPS
L. Sutanto, DNP, MHSA, RN, NE-BC, CPN

EBP Medical Director Responsible for Reviewing the Literature

K. Berg, MD, FAAP

EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document

M. Gripka, MT (ASCP) SM

Acronyms Used in this Document

Acronym	Explanation
CAT	Critically Appraised Topic
CSS	Clinical severity score
EBP	Evidence Based Practice
HS	Hypertonic saline
LOS	Length of stay
NS	Normal saline
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SC	Standard care

Statistical Acronyms Used in this Document

Statistical Acronym	Explanation
CI	Confidence Interval
M or \bar{x}	Mean
Mdn	Median
n	Number of cases in a subsample
N	Total number in sample
OR	Odds Ratio
P or p	Probability of success in a binary trial
RCT	Randomized controlled trial
SD	Standard deviation
SR	Systematic Review

Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)^d




Figure 1

Risk of Bias Summary

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Alatwani 2021	?	?	?	?	+	+	?
Everard 2014	+	+	+	+	?	+	?
Flores 2016	+	+	+	+	+	+	+
Hmar 2021	+	?	?	?	+	+	+
Islam 2018	+	+	+	+	+	+	+
Jaquet-Pilloud 2019	+	+	+	+	+	+	+
Kose 2016	+	?	?	?	+	+	+
Mahesh Kumar 2013	+	+	?	?	+	+	?
Morikawa 2018	+	+	+	+	+	+	+
Ojha 2014	+	+	+	+	+	+	?
Pandit 2013	+	+	+	+	+	+	+
Sharma 2013	+	+	+	+	+	?	?
Silver 2015	+	+	+	+	+	+	+
Teunissen 2014	+	+	+	?	+	+	+
Wu 2014	+	+	+	+	+	+	+

Summary of Findings Table

Table 1

Summary of Findings Table^a: Bronchiolitis- Hypertonic Saline

Participants (studies) Follow-up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall certainty of evidence	Study event rates (%)		Relative effect (95% CI)	Risk difference with nebulized 3% hypertonic saline
							With no nebulized 3% hypertonic saline	With nebulized 3% hypertonic saline		
LOS (hours)										
1449 (11 RCTs)	serious ^a	not serious	serious ^{b,c,d}	not serious	none	⊕⊕○○ Low	741	708	-	MD 6.47 lower (12.72 lower to 0.22 lower)
LOS (hours) subgroup: High or unclear risk of bias										
1018 (7 RCTs)	serious ^a	not serious	serious ^{b,c,d}	serious ^e	none	⊕○○○ Very low	512	506	-	MD 6 lower (13.49 lower to 1.5 higher)
LOS (hours) sub group: Low risk of bias										
431 (4 RCTs)	not serious	not serious	serious ^{b,c,d}	serious ^f	none	⊕⊕○○ Low	229	202	-	MD 7.17 lower (20.4 lower to 6.07 higher)

LOS (hours) subgroup: HS vs SC										
413 (2 RCTs)	serious ^a	not serious	not serious	serious ^f	none	⊕⊕○○ Low	210	203	-	MD 2.43 lower (13.41 lower to 8.54 higher)
LOS (hours) subgroup: HS vs NS										
1036 (9 RCTs)	serious ^a	serious ^g	serious ^{c,d}	serious ^e	none	⊕○○○ Very low	531	505	-	MD 7.29 lower (14.78 lower to 0.2 higher)
LOS (hours) subgroup: No beta agonist or adrenaline included in nebulization										
562 (4 RCTs)	serious ^a	not serious	serious ^d	serious ^f	none	⊕○○○ Very low	286	276	-	MD 6.04 lower (15.19 lower to 3.12 higher)
LOS (hours) subgroup: Beta agonist or adrenaline included in nebulization										
887 (7 RCTs)	serious ^a	serious ^g	serious ^c	serious ^f	none	⊕○○○ Very low	455	432	-	MD 6.86 lower (16.11 lower to 2.4 higher)

LOS (hours) subgroup: Treatment administered every 4 hours										
376 (2 RCTs)	serious ^a	not serious	serious ^c	serious ^f	none	⊕○○○ Very low	188	188	-	MD 0.22 higher (5.22 lower to 5.66 higher)
LOS (hours) subgroup: Treatment administered every 6 hours										
779 (6 RCTs)	serious ^a	not serious	serious ^d	serious ^f	none	⊕○○○ Very low	393	386	-	MD 8.52 lower (17.23 lower to 0.19 higher)
LOS (hours) subgroup: Treatment administered every 8 hours										
294 (3 RCTs)	serious ^a	not serious	serious ^c	serious ^f	none	⊕○○○ Very low	160	134	-	MD 9.9 lower (23.49 lower to 3.68 higher)
LOS (hours): Studies not included in meta-analysis										
418 (3 RCTs)	serious ^a	not serious	serious ^{c,d}	serious ^h	none	⊕○○○ Very low	203	215	-	not pooled
Wang CSS following 1 day of treatment										
296 (3 RCTs)	serious ^a	not serious	serious ⁱ	serious ^h	none	⊕○○○ Very low	149	147	-	MD 0.76 lower (1.07 lower to 0.46 lower)

Wang CSS following 2 days of treatment										
226 (2 RCTs)	serious ^a	not serious	serious ⁱ	serious ^h	none	⊕○○○ Very low	114	112	-	MD 0.54 lower (0.79 lower to 0.28 lower)
Wang CSS following 3 days of treatment										
168 (2 RCTs)	not serious	serious ^g	serious ⁱ	serious ^h	none	⊕○○○ Very low	85	83	-	MD 1.19 lower (1.67 lower to 0.71 lower)
Need for Supplemental O2										
430 (4 RCTs)	serious ^{a,j}	not serious	serious ^k	serious ^h	none	⊕○○○ Very low	97/214 (45.3%)	92/216 (42.6%)	OR 0.88 (0.57 to 1.34)	31 fewer per 1,000 (from 132 fewer to 73 more)
Duration of Supplemental O2 (hours)										
346 (5 RCTs)	serious ^a	not serious	serious ^{c,k}	serious ^f	none	⊕○○○ Very low	173	173	-	MD 5.84 lower (11.41 lower to 0.28 lower)


Explanations

- a. Lack of blinding or unclear description of blinding
- b. Control varied among studies as either nebulized NS or no nebulized treatment
- c. Variation in administration of beta agonist or adrenaline
- d. Variation in frequency of administration of nebulized HS
- e. Wide CI
- f. Low number of participants, wide CI
- g. Unexplained heterogeneity
- h. Low number of participants
- i. Variation in baseline CSS scores
- j. Attrition bias
- k. Variation in hospital criteria for O2 requirement

Meta-analysis(es)

Figure 2

Comparison: HS versus no HS, Outcome: LOS (hours)



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Figure 3
Comparison: HS versus no HS, Outcome: LOS (hours), Subgroups: High or unclear risk of bias versus low risk of bias




Figure 4
Comparison: HS versus no HS, Outcome: LOS (hours), Subgroups: HS versus NS, HS versus standard care (SC)






Figure 5
Comparison: HS versus no HS, Outcome: LOS (hours), Subgroups: HS with beta agonist or adrenaline versus NS or SC with beta agonist (BA) or adrenaline, HS without BA or adrenaline versus NS or SC without BA or adrenaline



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Figure 6
Comparison: HS versus no HS, Outcome: LOS (hours), Subgroups: HS administered every 4 hours, HS administered every 6 hours, HS administered every 8 hours



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Figure 7
Comparison: HS versus no HS, Outcome: CSS following 1 day of treatment



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias


Figure 8
Comparison: HS versus no HS, Outcome: CSS following 2 days of treatment



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Figure 9
Comparison: HS versus no HS, Outcome: CSS following 3 days of treatment




Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Figure 10

Comparison: HS versus no HS, Outcome: Need for Supplemental Oxygen



Risk of bias legend

- (A) Random sequence generation (selection bias)
- (B) Allocation concealment (selection bias)
- (C) Blinding of participants and personnel (performance bias)
- (D) Blinding of outcome assessment (detection bias)
- (E) Incomplete outcome data (attrition bias)
- (F) Selective reporting (reporting bias)
- (G) Other bias

Characteristics of Intervention Studies
Alatwani et al., (2021)

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children < 18 months of age with moderate or severe bronchiolitis from November 1, 2016 through January 30, 2018 Setting: Teaching hospital in Karbala Randomized into study: $N = 161$</p> <ul style="list-style-type: none"> • Group 1, 4mL of 3% hypertonic saline nebulizer*: $n = 83$ • Group 2, conventional treatment as ordered by physician: $n = 78$ <p>Completed Study: $N = 159$</p> <ul style="list-style-type: none"> • Group 1: $n = 83$ • Group 2: $n = 76$ <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: $n = 45$ (54%) • Group 2: $n = 41$ (53%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (Frassanito et al.)</p> <ul style="list-style-type: none"> • Group 1: 6.37 (17 days to 18 months) • Group 2: 6.21 (17 days to 18 months) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children < 18 months of age with severe or moderate bronchiolitis admitted to the hospital • History of upper respiratory viral infection which included: <ul style="list-style-type: none"> ○ Wheezing ○ Crackles in chest ○ Oxygen saturation levels < 94% ○ Respiratory distress measured by Respiratory Distress Assessment Instrument (RDAI) score > 4 (scoring determined based on respiratory rate, use of accessory muscles, pallor, and auscultatory findings) <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Children with a reported recent episode of wheezing • Children with history of chronic cardiopulmonary disease or immunodeficiency • Children who were critically ill on presentation • Children who were referred to the intensive care unit <p>Power Analysis: Not reported</p>
<p>Interventions</p>	<p>Both: Inhaled therapies were used by infants considered to be in stable condition. A tight-fitting mask or head box was used to administer. Clinical response was determined by using the RDAI and oxygen saturation levels at the beginning of the study and three times a day during the study.</p> <ul style="list-style-type: none"> • Group 1, 4mL of 3% hypertonic saline nebulizer: Received nebulized solution a few hours after admission, then every 6 hours • Group 2, conventional treatment as ordered by physician: Conventional treatment was not specified
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of hospital stay* • Oxygen saturation levels* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Not reported <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>

Evidence Based Practice

Notes	<p>Results:</p> <ul style="list-style-type: none"> The two patients from the control group were unable to complete due to condition deterioration, both were in the control group Children between the ages of 0-6 months (56%) were more likely to require hospitalization when comparing to children between the ages of 7-12 months or 13-18 months (44%). Improvement in oxygen saturation within the first two days of treatment was most rapid in the intervention group when compared to the control group (see <i>table</i>) Mean hospital length of stay in days was shorter for the hypertonic saline group (3.38) versus the normal saline group (4.67), a reduction of 1.3 days (27.8%), $p = .001$. Majority of the children included in the study were < 12 months of age, of which 57% ($n = 47$) in the intervention group and 55% ($n = 43$) in the control group were between the ages of 0-6 months. <p>Length of Stay, n (%)</p> <table border="1"> <thead> <tr> <th>Days</th> <th>3% HS ($n = 83$)</th> <th>Conventional Treatment ($n = 78$)</th> </tr> </thead> <tbody> <tr> <td>3 days</td> <td>44 (53%)</td> <td>36 (46%)</td> </tr> <tr> <td>3-6 days</td> <td>39 (47%)</td> <td>22 (28%)</td> </tr> <tr> <td>> 6 days</td> <td>0 (0%)</td> <td>20 (26%)</td> </tr> </tbody> </table> <p>Limitations: Not reported</p>	Days	3% HS ($n = 83$)	Conventional Treatment ($n = 78$)	3 days	44 (53%)	36 (46%)	3-6 days	39 (47%)	22 (28%)	> 6 days	0 (0%)	20 (26%)
Days	3% HS ($n = 83$)	Conventional Treatment ($n = 78$)											
3 days	44 (53%)	36 (46%)											
3-6 days	39 (47%)	22 (28%)											
> 6 days	0 (0%)	20 (26%)											

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The study did not report how children were randomized into the study
Allocation concealment (selection bias)	Unclear risk	The study did not report on how children were allocated to intervention groups
Blinding of participants and personnel (performance bias)	Unclear risk	The study did not report on how personnel were blinded for the study
Blinding of outcome assessment (detection bias)	Unclear risk	Hospital length of stay and oxygen saturation levels were the outcomes assessed. It is unclear of the parameters established for hospital discharge which may have impacted length of stay
Incomplete outcome data (attrition bias)	Low risk	Outcomes for the total number of participants were reported
Selective reporting (reporting bias)	Low risk	All pre-determined outcomes were reported
Other bias	Unclear risk	Conflict of interest, funding not reported

Everard et al., 2014

Methods	Randomized Control Trial
Participants	<p>Participants: Healthy infants under 1 year of age needing supplementary oxygen for oxygen saturations of <92% when admitted to the hospital with a diagnosis of acute bronchiolitis, between October of 2011 and December 2013.</p> <p>Setting: United Kingdom, ten sites in England and Wales, including teaching hospitals and district general hospitals.</p> <p>Randomized into study: $N = 317$</p> <ul style="list-style-type: none"> • Group 1, Standard supportive care (SC): $n = 159$ • Group 2, SC and nebulized 3% hypertonic saline (HS): $n = 158$ <p>Completed Study: $N = 290$</p> <ul style="list-style-type: none"> • Group 1: $n = 149$ • Group 2: $n = 142$ <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: $n = 85$ (57.0%) • Group 2: $n = 73$ (51.4%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean (SD) / median (IQR) in months</p> <ul style="list-style-type: none"> • Group 1: 3.4 (2.8) / 2.5 (0.3 to 11.5) • Group 2: 3.3 (2.6) / 2.3 (0.3 to 11.5) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Healthy infants under 1 year of age • Apparent viral respiratory tract infection • Associated with airway obstruction, as indicated by <ul style="list-style-type: none"> ○ Hyperinflation ○ Tachypnea ○ Subcostal recession ○ Widespread crepitations on auscultation • Supplemental oxygen therapy required at admission <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • History of <ul style="list-style-type: none"> ○ Wheezy bronchitis ○ Asthma ○ Gastroesophageal reflux ○ Previous lower respiratory tract infections • Risk factors for severe disease • Caregiver lacking fluent English in the absence of translational services. • Patients requiring admission to high dependency or intensive care units (HDU/ICU) at presentation. <p>Power Analysis: Not reported</p>
Interventions	<p>Both: All study participants received SC which includes supplemental oxygen as required, minimal handling to avoid exhaustion and fluid administration. Discontinuation of previously prescribed antibiotics was encouraged but were permissible for suspected secondary bacterial infection as per United Kingdom guidance.</p> <ul style="list-style-type: none"> • Group 1: SC only • Group 2: SC plus HS, administered every six hours by a nurse, via the PARI Sprint nebulizer with appropriate face mask.
Outcomes	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of time until the infant was assessed at fit for discharge, defined as <ul style="list-style-type: none"> ○ Adequate feeding, taking >75% of their usual intake. ○ Tolerating room air with an oxygen saturation of at least 92% for six hours.

Evidence Based Practice

	<p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Time to actual discharge* • Readmission within 28 days from randomization • Adverse events* • Healthcare usage • Duration of respiratory symptoms post discharge. <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> • There was no difference between the infants receiving standard supportive care plus nebulized 3% hypertonic saline and the infants that received standard care alone. Nebulized HS does not reduce the length of stay or the length of time until being declared fit for discharge in infants hospitalized with acute bronchiolitis. • Adverse events: <ul style="list-style-type: none"> ○ Six adverse events were possibly related to HS treatment, including one serious adverse event (SAE), bradycardia and desaturation during administration of the nebulizer, which resolved the following day. ○ The remaining five non-SAEs were: <ul style="list-style-type: none"> ▪ Bradycardia (self-correcting) ▪ Desaturation (resolved in one day) ▪ Coughing fit (resolved in one day) ▪ Increased respiratory rate (resolved in one day) ▪ Chest infection (resolved after six days) ○ Although one infant in the HS group developed bradycardia with desaturation, there were no statistically significant differences in the incidence of adverse events between the control group and intervention group. • As per the study authors, this study does not support the use of HS in the treatment of acute bronchiolitis. <p>Limitations:</p> <ul style="list-style-type: none"> • A potential limitation of the study is the absence of blinding, but the study authors propose no blinding as a strength, because it removes potential confounders due to other nebulized interventions. • Restrictive time window within which it was permissible to randomize, limited inclusion of otherwise eligible infants. • The definition of acute bronchiolitis varies from country to country. The standard British definition is more restrictive and may have influenced study outcomes (p. 1110). • The study was not powered for secondary outcomes.

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Infants were randomized using a centralized web-based randomization system with a computer generated algorithm generated by Sheffield Clinical Trials Research Unit. Randomization was conducted in randomly ordered blocks of size two, four and six stratified by hospital.
Allocation concealment (selection bias)	Low risk	See selection bias note.
Blinding of participants and personnel (performance bias)	High risk	There was no blinding due to the study design. However, the data was collected at ten sites, using measurable, routinely recorded clinical information, obtained by nurses caring for patients. The authors argue that, "It is extremely unlikely that any systematic view of the potential benefits or harm would influence the many dozens of medical staff involved in the care of these infants."
Blinding of outcome assessment (detection bias)	Low risk	Outcome measurement is unlikely to be influenced by a lack of blinding.
Incomplete outcome data (attrition bias)	Unclear risk	The study authors account for all missing outcome data including lack of recorded date and time of fit for discharge for a group of patients and five patients that did not receive treatment as scheduled and noted that the missing data was unlikely to have impacted the outcome.
Selective reporting (reporting bias)	Low risk	The study protocol is well described and outcomes have been reported in a pre-specified way.
Other bias	Unclear risk	The study notes that the funder was not involved in the study design, patient recruitment, data collection, analysis, interpretation, writing or publication of the report.

Evidence Based Practice

Flores-González et al., 2016

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Infants aged less than 12 months with acute bronchiolitis. Setting: Pediatric department of a general urban hospital in Lisbon, Portugal Randomized into study: <i>N</i> = 78</p> <ul style="list-style-type: none"> • Group 1, 3% Hypertonic saline: <i>n</i> = 38 • Group 2, 0.9% Saline: <i>n</i> = 40 <p>Completed Study: <i>N</i> = 68</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 33 • Group 2: <i>n</i> = 35 <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 18 (54.4%) • Group 2: <i>n</i> = 18 (51.4%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (+/- SD):</p> <ul style="list-style-type: none"> • Group 1: 3.3 (+/- 2.4 months) • Group 2: 3.8 (+/- 2.5 months) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Infants < 12 months of age. • Diagnosis of acute viral bronchiolitis (defined as an apparent viral respiratory tract infection diagnosed in an infant with nasal discharge and wheezy cough, in the presence of fine inspiratory crackles and/or high pitched expiratory wheeze, in which apnea could be a presenting feature). <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Previous episodes of wheezing. • Personal history of prematurity (gestational age <34 weeks). • Physician diagnosis of eczema, or food allergy. • Physician diagnosis of chronic disease (cardiac, respiratory, immunological, neurological, or metabolic). • High severity criteria (coma, respiratory rate >80 breaths/minute, oxygen saturation on <88% on room air or need for assisted ventilation). • Refused to participate. <p>Power Analysis:</p> <ul style="list-style-type: none"> • For hospital days with admission for bronchiolitis, the study needs a sample size of 31 infants in each group for an alpha of 0.05 and a power of 90% • For a clinically significant change in severity score, the study needs a sample size of 33 infants in each group for an alpha of 0.05 and a power of 90%.
<p>Interventions</p>	<p>Both: Prior to enrollment, all infants underwent deep nasal suctioning with nasal 0.9% saline drops, and a trial nebulization of salbutamol (1.25 mg in 3 ml of NS). After randomization 0.25 ml (1.25 mg) of salbutamol was added to each 3 ml aliquot of saline.</p> <ul style="list-style-type: none"> • Group 1: 3% hypertonic saline via nebulization • Group 2: 0.9% normal saline via nebulization
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Efficacy of inhaled hypertonic saline vs normal saline on length of stay* • Efficacy of inhaled hypertonic saline vs normal saline on severity scores (Wang) in infants with acute viral bronchiolitis* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Need for supplemental oxygen* • Need for tube feeding • Need for add-on therapies (further doses of salbutamol, nebulized epinephrine, systemic corticosteroids, antibiotics, or diuretics)

Evidence Based Practice

	<p>Safety outcome(s):</p> <ul style="list-style-type: none"> Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
Notes	<p>Results:</p> <ul style="list-style-type: none"> No difference was found in time until patients were fit for discharge, time until discharge, severity scores, need for supplemental oxygen, need for tube feeding, or need for add on medications. <p>Limitations:</p> <ul style="list-style-type: none"> Could not reliably rule out other causes of infant wheezing (like asthma) Local practices of diagnosis and treatment may have differed. Average length of stay is higher in study country compared to USA, Israel, and the Netherlands. The study was not powered for secondary outcomes.

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Used a computer random number generator.
Allocation concealment (selection bias)	Low risk	The randomization list was concealed by the Pharmacy.
Blinding of participants and personnel (performance bias)	Low risk	Both solutions were similar in appearance and smell, stored in identical syringes, labeled only by a code number, and stored in the same refrigerator.
Blinding of outcome assessment (detection bias)	Low risk	Patients were clinically evaluated from study inclusion until discharge by the same investigator.
Incomplete outcome data (attrition bias)	Low risk	Patients who were excluded during the study were accounted for (clinical deterioration with need for ICU).
Selective reporting (reporting bias)	Low risk	All primary outcomes reported.
Other bias	Low risk	No conflict of interest or funding source concerns.

Evidence Based Practice

Hmar et al., (2021)

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children between the ages of 3 months and 2 years with acute bronchiolitis admitted between September 2016 through August 2018 Setting: Pediatric ward or Regional Institute of Medial Sciences, Imphal, Manipur (India) Randomized into study: $N = 158$</p> <ul style="list-style-type: none"> • Group 1, 3% hypertonic saline (HS): $n = 79$ • Group 2, 0.9% normal saline (NS): $n = 79$ <p>Completed Study: $N = 158$</p> <ul style="list-style-type: none"> • Group 1: $n = 79$ • Group 2: $n = 79$ <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: $n = 42$ (53.2%) • Group 2: $n = 48$ (61%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (SD)</p> <ul style="list-style-type: none"> • Group 1: 10.02 ± 5.45 • Group 2: 8.45 ± 4.88 <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children between the ages of 3 months to 2 years of age • Children with features of acute bronchiolitis <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Children diagnosed with: <ul style="list-style-type: none"> ○ Bacterial or aspiration pneumonia ○ Previous wheezing episodes ○ Oxygen saturation < 92% in room air ○ Cyanosis ○ Obtunded consciousness ○ Progressive respiratory failure ○ Requiring mechanical ventilation ○ Foreign body inhalation ○ Cardiac disease ○ Congenital malformations • Parents refusing consent <p>Power Analysis: 80% and 5% error (95% CI)</p>
<p>Interventions</p>	<p>Both: Nebulization was completed using the Apex Eco-Plus nebulizer made by Apex Medical Corp, France. All patients were enrolled with 24 hours of hospital admission, examined, and re-examined every day at treatment time. Patients in each group received four treatments each day of their hospital stay which were delivered every 6 hours until ready for discharge (absence of fever and respiratory distress, breathing room air comfortably with saturation > 96%, and tolerating oral feeds). Any additional inhalations were recorded and calculated as an add-on therapy. Clinical parameters were measured and recorded using a CS score (Wang et al., 1992). Antibiotics were used in the presence of fever, leukocytosis, and chest x-ray infiltrations.</p> <ul style="list-style-type: none"> • Group 1, 3% HS: Received salbutamol inhalation in 3 mL of 3% saline solution • Group 2, 0.9% NS: Received inhalation of salbutamol in 3 mL of 0.9% saline solution
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Improvement in respiratory distress-clinical severity (CS)* • Length of hospital stay (LOS)* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Not reported

Evidence Based Practice

	<p>Safety outcome(s):</p> <ul style="list-style-type: none"> Adverse effects or worsening of symptoms <p>*Outcomes of interest to the CMH CPG or CAT development team</p>																				
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> The maximum number of cases occurred in the > 6-12 months age group (HS, $n = 46$ (58.2%); NS, $n = 36$ (45.6%)) Nebulized salbutamol diluted with 3% HS produced a clinically significant reduction ($p = < 0.001$) in the CS scores as compared to treatment with NS as a diluent following treatment on both the second day of admission (2.21 ± 1.10 (HS); 3.05 ± 1.17 (NS)) and the third day of admission (1.46 ± 0.63 (HS); 2.01 ± 0.99 (NS)) The mean LOS was significantly lower ($p = < 0.0001$) and one day shorter in the HS group (4.98 ± 1.35 days) than the NS group (5.84 ± 1.18 days). There were no reported adverse effects or worsening of symptoms between groups <table border="1" data-bbox="427 751 1242 903"> <thead> <tr> <th colspan="4">Mean (SD) Clinical Severity Scores</th> </tr> <tr> <th>Day of Admission</th> <th>HS Group</th> <th>NS Group</th> <th><i>p</i> - value</th> </tr> </thead> <tbody> <tr> <td>Admission</td> <td>3.98 ± 1.20</td> <td>3.75 ± 1.06</td> <td>0.209</td> </tr> <tr> <td>Second Day</td> <td>2.21 ± 1.10</td> <td>3.05 ± 1.17</td> <td>< 0.001</td> </tr> <tr> <td>Third Day</td> <td>1.46 ± 0.63</td> <td>2.01 ± 0.99</td> <td>< 0.001</td> </tr> </tbody> </table> <p>Limitations:</p> <ul style="list-style-type: none"> Diagnosis of bronchiolitis was based on clinical considerations as virological diagnostic facilities were not available Generalizations of findings are limited due to the reduced number of participants and single study site. The study was not powered for secondary outcomes. 	Mean (SD) Clinical Severity Scores				Day of Admission	HS Group	NS Group	<i>p</i> - value	Admission	3.98 ± 1.20	3.75 ± 1.06	0.209	Second Day	2.21 ± 1.10	3.05 ± 1.17	< 0.001	Third Day	1.46 ± 0.63	2.01 ± 0.99	< 0.001
Mean (SD) Clinical Severity Scores																					
Day of Admission	HS Group	NS Group	<i>p</i> - value																		
Admission	3.98 ± 1.20	3.75 ± 1.06	0.209																		
Second Day	2.21 ± 1.10	3.05 ± 1.17	< 0.001																		
Third Day	1.46 ± 0.63	2.01 ± 0.99	< 0.001																		

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Standard randomization table used
Allocation concealment (selection bias)	Unclear risk	Participant selection procedures were not described in the study. There was insufficient information to permit judgement of low or high risk.
Blinding of participants and personnel (performance bias)	Unclear risk	Participant and personnel blinding mechanisms were not reported. There was insufficient information to permit judgement of low or high risk.
Blinding of outcome assessment (detection bias)	Unclear risk	The methods for collecting and analyzing data were not clearly described in the study. There was insufficient information to permit judgement of low or high risk.
Incomplete outcome data (attrition bias)	Low risk	All individuals randomized within the study were analyzed
Selective reporting (reporting bias)	Low risk	Data was presented for all study outcomes identified
Other bias	Low risk	There were no concerns for other bias.

Evidence Based Practice

Islam et al., 2018

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children one month to two years of age presenting with symptoms of bronchiolitis between January 2013 to December 2013 Setting: Dhaka Medical College Hospital, department of pediatrics Randomized into study: <i>N</i> = 90</p> <ul style="list-style-type: none"> • Group 1, 3% hypertonic saline (HS) nebulization: <i>n</i> = 45 • Group 2, 0.9% normal saline (NS) nebulization: <i>n</i> = 45 <p>Completed Study: <i>N</i> = 90</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 45 • Group 2: <i>n</i> = 45 <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 25 (55.5%) • Group 2: <i>n</i> = 26 (57.7%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (standard deviation or SD)</p> <ul style="list-style-type: none"> • Group 1: 5.2 ± 3.2 • Group 2: 5.5 ± 3.0 <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children between one month and two years of age • Children presenting with: <ul style="list-style-type: none"> ○ Preceding or existing runny nose ○ Cough ○ Breathing difficulty ○ Chest in-drawing (increased work of breathing) and rhonchi (airway sounds) on auscultation • Children admitted between January 2013 to December 2013 <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • None reported <p>Power Analysis: Not reported</p>
<p>Interventions</p>	<p>Both: Relevant history and physical examination findings were recorded via a pre-tested, semi-structured questionnaire. Clinical severity scores were obtained using the respiratory distress assessment instrument. Oxygen saturation in room air was measured using a pulse oximeter and recorded on admission. Each group received the same supportive measures (propped up positioning, suction when needed, fluid, feeding, oxygen therapy (when oxygen saturation < 90%), paracetamol for fever, and counseling.</p> <ul style="list-style-type: none"> • Group 1, 3% HS nebulization: Received 4 mL of 3% hypertonic saline nebulization three times daily at 8 hour intervals until appropriate for discharge • Group 2, 0.9% NS nebulization: Received 4 mL of 0.9% normal saline nebulization three times daily at 8 hour intervals until appropriate for discharge
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Clinical severity score measured using the Respiratory Distress Assessment Instrument (RDAI; Wang et al., 1992)* • Length of hospital stay* • Oxygen saturation in room air • Duration of oxygen supplementation* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • None reported <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Adverse event (Side effect of medications) <p>*Outcomes of interest to the CMH CPG or CAT development team</p>

Evidence Based Practice

Notes	<p>Results:</p> <ul style="list-style-type: none"> • Difference between groups regarding age ($p = .82$) and sex ($p = .50$) were not significant • All children in both groups presented with runny nose, cough, breathing difficulty, chest in-drawing, and lung sounds. However, feeding difficulty was a presenting feature in 55.5% of the children in the 3% HS group and 57.7% of the children in the 0.9% NS group • Clinical severity score of both treatment groups reduced. However, reduction was more significant in children who received 3% HS (<i>see table</i>) • Of those requiring oxygen therapy, children in the 3% HS group required 15 hours on average, whereas children in the 0.9% NS group required 26.4 hours on average. The duration of oxygen between groups was significantly reduced in the 3% HS intervention group (<i>see table</i>) • Forty-two (93.3%) of the children in the 3% HS group recovered and discharged within 72 hours, whereas 26 (57.8%) of the children in the 0.9% NS group recovered and discharged within the same time period. • When comparing interventions, length of stay was significantly less ($p = .001$) in the 3% HS group • No adverse events were identified in either the 3% HS group, nor the 0.9% NS group 																												
	<p style="text-align: center;">Clinical Severity Score</p> <table border="1"> <thead> <tr> <th>Timeframe</th> <th>3% HS ($n = 45$)</th> <th>0.9% NS ($n = 45$)</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Baseline</td> <td>9.0 ± 1.0</td> <td>9.3 ± 1.8</td> <td>0.943</td> </tr> <tr> <td>12 hours</td> <td>8.2</td> <td>9.0</td> <td>Not reported</td> </tr> <tr> <td>24 hours</td> <td>5.3</td> <td>7.8</td> <td>Not reported</td> </tr> <tr> <td>36 hours</td> <td>4.3</td> <td>6.1</td> <td>Not reported</td> </tr> <tr> <td>48 hours</td> <td>2.6</td> <td>4.3</td> <td>Not reported</td> </tr> <tr> <td>60 hours</td> <td>2.9</td> <td>4.5</td> <td>Not reported</td> </tr> </tbody> </table>	Timeframe	3% HS ($n = 45$)	0.9% NS ($n = 45$)	p -value	Baseline	9.0 ± 1.0	9.3 ± 1.8	0.943	12 hours	8.2	9.0	Not reported	24 hours	5.3	7.8	Not reported	36 hours	4.3	6.1	Not reported	48 hours	2.6	4.3	Not reported	60 hours	2.9	4.5	Not reported
Timeframe	3% HS ($n = 45$)	0.9% NS ($n = 45$)	p -value																										
Baseline	9.0 ± 1.0	9.3 ± 1.8	0.943																										
12 hours	8.2	9.0	Not reported																										
24 hours	5.3	7.8	Not reported																										
36 hours	4.3	6.1	Not reported																										
48 hours	2.6	4.3	Not reported																										
60 hours	2.9	4.5	Not reported																										
	<p style="text-align: center;">Duration of Oxygen Therapy</p> <table border="1"> <thead> <tr> <th>Duration of Oxygen Therapy</th> <th>3% HS ($n = 4$)</th> <th>0.9% NS ($n = 5$)</th> <th>p-value</th> </tr> </thead> <tbody> <tr> <td>Mean ± SD</td> <td>15.0 ± 6.0</td> <td>26.4 ± 5.4</td> <td>0.02</td> </tr> </tbody> </table>	Duration of Oxygen Therapy	3% HS ($n = 4$)	0.9% NS ($n = 5$)	p -value	Mean ± SD	15.0 ± 6.0	26.4 ± 5.4	0.02																				
Duration of Oxygen Therapy	3% HS ($n = 4$)	0.9% NS ($n = 5$)	p -value																										
Mean ± SD	15.0 ± 6.0	26.4 ± 5.4	0.02																										
	<p>Limitations:</p> <ul style="list-style-type: none"> • Study occurred at a single site with a small sample size 																												

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization was completed by lottery method. The parents or caregivers were given a chance to select a sealed encoded envelope from a box containing eight envelopes (four sealed envelopes designated for each intervention).
Allocation concealment (selection bias)	Low risk	The intervention allocation was randomized using a lottery method of which sealed encoded envelopes were used.
Blinding of participants and personnel (performance bias)	Low risk	While not overtly addressed, it appears the participants may have been blinded through mention of the following statement, "there was no detectable difference in color, smell, or other physical properties existed between 0.9% saline solution and 3% saline solution"
Blinding of outcome assessment (detection bias)	Low risk	No blinding of outcome assessment. However, the review author judges that the outcome measurement is not likely to be influenced by lack of blinding
Incomplete outcome data (attrition bias)	Low risk	There is no missing outcome data
Selective reporting (reporting bias)	Low risk	The report includes all expected outcomes
Other bias	Low risk	The study appears to be free of other sources of bias

Evidence Based Practice

Jaquet-Pilloud et al., 2019

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children, aged 6 weeks to 2 years, with acute bronchiolitis presenting to the Emergency Department (ED), between April 2013 and March 2016 Setting: Switzerland, One secondary care center and tertiary care hospital Randomized into study: <i>N</i> = 122</p> <ul style="list-style-type: none"> • Group 1, Nebulized 3% hypertonic saline in addition to supportive care: <i>n</i> = 61 • Group 2, Standard supportive care: <i>n</i> = 61 <p>Completed Study: <i>N</i> = 120</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 61 • Group 2: <i>n</i> = 59 <p>Gender, female/male:</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 22 (36%) • Group 2: <i>n</i> = 22 (37.3%) <p>*Reporting by author does not specify gender is provided</p> <p>Race / ethnicity or nationality:</p> <ul style="list-style-type: none"> • Not reported <p>Age, median in months, (range)</p> <ul style="list-style-type: none"> • Group 1: 6.3 (1.4 to 21.4) • Group 2: 6.1 (1.4 - 21.9) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children aged 2 weeks to 24 months • First episode of acute bronchiolitis (defined as symptoms of upper respiratory tract infection in addition to tachypnea, wheezing and widespread crackles breath sounds) • Wang Score of 5 - 12 (moderate to severe) on arrival <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Mild bronchiolitis (Wang Score < 5) • Previous episodes of wheezing, cardiac or chronic respiratory disease • Immunocompromised children • Gestation age < 34 weeks • Critical illness requiring immediate admission to Intensive Care Unit (ICU) • RSV immunoglobulin therapy or corticosteroid therapy in previous 2 weeks • Bronchodilator use 24 hours prior to presentation <p>Power Analysis: With a sample size of 60 in each arm there would be a power of 80% to detect a significant difference (<i>p</i> < .05)</p>
<p>Interventions</p>	<p>Both: Suctioning nasal secretions, water-electrolyte balance, supplemental oxygen, if needed. Nebulized epinephrine 4mg if signs of respiratory failure</p> <ul style="list-style-type: none"> • Group 1: 4 mL of NaCl 3% nebulized every 6 hours until discharge • Group 2: No additional interventions
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of stay* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Duration of oxygen therapy* • Need for nebulized epinephrine • Transfer to ICU* • Adverse events • Readmission within 7 days of discharge <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>

Evidence Based Practice

Notes	<p>Results</p> <ul style="list-style-type: none"> • There was no significant difference for mean length of stay in hours between the nebulized saline group (47) and the standard care group (50.4), difference of - 3.4, 95% CI [-17.05, 10.25]. • No significant differences between groups for mean duration of oxygen therapy, a difference of -1.6 hours, 95% CI [-13.15, 9.95] • No significant differences between groups for racemic epinephrine rescue therapy, transfer to pediatric intensive care unit, or readmission within 7 days after discharge. <p>Limitations</p> <ul style="list-style-type: none"> • Absence of blinding • No use of active comparator (placebo) • Not controlled for duration of illness prior to hospitalization • Low statistical power for secondary outcomes and completion of sensitivity analysis <p>Additional Information</p> <ul style="list-style-type: none"> • Reported results as intention to treat but did not include all patients randomized into study (61 in each arm). Analysis did not include two subjects that were excluded following randomization. In the flow chart in Figure 1, it appears that one subject in each arm was excluded, however in the results section and Tables 1 and 2, it appears that both excluded subjects were from the group receiving only supportive care. Following our sensitivity analysis, we determined this would not have a significant effect on the results of the study. • Ten participants did not receive treatment as expected. • Five patients were admitted to hospital again within 7 days after discharge. Two patients in each group were readmitted for persisting symptoms of bronchiolitis (cough, nasal obstruction) and one patient had gastroenteritis.
--------------	---

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomly allocated on a 1:1 basis using a computer-generated randomization program in blocks of 10
Allocation concealment (selection bias)	High risk	Allocation did not appear to be concealed
Blinding of participants and personnel (performance bias)	Low risk	Blinding of participants and personnel not possible due to nature of intervention (use of nebulized saline vs. no use of nebulized saline) and lack of use of placebo in protocol, but lack of blinding of participants and personnel not likely to affect outcome
Blinding of outcome assessment (detection bias)	High risk	Physicians in charge of the ward assessed the Wang Score and did not appear to be blinded. As this is subjective, bias is possible. Equipment for 3% hypertonic saline may be in the patient's room.
Incomplete outcome data (attrition bias)	Low risk	Statistical analysis claimed to follow intention to treat principle but did not include two patients in standard care arm excluded after randomization. However, our sensitivity analysis showed that including these patients in analysis did not affect results.
Selective reporting (reporting bias)	Low risk	All outcomes defined a priori were reported.
Other bias	Low risk	The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. No competing interests declared

Evidence Based Practice

Kose et al., 2016

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Infants, age 1 - 24 months Setting: Pediatric hospital setting between January 2014 and May 2014 Randomized into study: <i>N</i> = 104</p> <ul style="list-style-type: none"> • Group A, Salbutamol 0.15 mg/kg plus 2.5mL 0.9% saline <i>n</i> = 35 • Group B, Salbutamol 0.15 mg/kg plus 2.5mL 3% saline: <i>n</i> = 35 • Group C, Salbutamol 0.15 mg/kg plus 2.5mL 7% saline: <i>n</i> = 34 <p>Gender, males:</p> <ul style="list-style-type: none"> • Group A: <i>n</i> = 14 (66.67%) • Group B: <i>n</i> = 14 (66.67%) • Group C: <i>n</i> = 14 (70%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, Median in months (min - max):</p> <ul style="list-style-type: none"> • Group A: 7.6 (1 - 18) • Group B: 7.6 (2 - 23) • Group C: 7.7 (1 - 24) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Age 1 - 24 months • History of preceding viral upper respiratory infection followed by wheezing and crackles on auscultation • First wheezing episode • Clinical severity score (CSS) of ≥ 4 <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Infants with CSS < 4 • Oxygen saturation < 80% in room air • Chronic cardiopulmonary or neurological disease • Premature birth • Birth weight < 2500 g • History of recurrent wheezing episodes • Proven immune deficiency • Age < 1 month or > 2 years • Proven or suspected acute bacterial infection • Previous treatment with bronchodilators or corticosteroids • Presence of symptoms > 7 days • Consolidation or atelectasis on a chest roentgenogram <p>Power Analysis: The power of the study was 50% (no further information given as to number needed for power)</p>
<p>Interventions</p>	<ul style="list-style-type: none"> • Both: All patients received inhalation of 0.15 mg/kg salbutamol plus 2.5 mL of either 0.9%, 3% or 7% saline solution, twice upon admission at 30 minute intervals and then every 6 hours until discharge • Group A: 0.9% inhaled saline • Group B: 3% inhaled saline • Group C: 7% inhaled saline
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Effect of study drugs on the length of hospital stay (LOS) <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Safety and efficacy in reducing the clinical severity score (CSS) at the 24 hours of the study <p>Safety outcome(s):</p>

Evidence Based Practice

	<ul style="list-style-type: none"> Side effects of study drugs including tachycardia, tremor, bronchospasm and cough <p>*Outcomes of interest to the CMH CPG or CAT development team</p>																																								
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> Median LOS in hours (min - max) was not significantly different in the group receiving 0.9% saline (72.0, (20 - 288)) vs. 3% saline (64.0, (12 - 168)) vs. 7% saline (60.0, (12 - 264)), $p = .760$ CSS scores were not significantly different between groups at 0 hours, $p = .778$, 1 hour, $p = .271$, or 24 hours, $p = .165$. In the group receiving 7% saline, bronchospasm was observed in two patients, cough during nebulization was observed in two patients, and both bronchospasm and cough during nebulization were observed in one additional patient. <table border="1" data-bbox="427 688 1445 840"> <thead> <tr> <th></th> <th colspan="3">Length of Stay</th> <th></th> </tr> <tr> <th></th> <th>Group A $n = 35$</th> <th>Group B $n = 35$</th> <th>Group C $n = 34$</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>LOS in hours (min - max)</td> <td>72.0 (20 - 288)</td> <td>64.0 (12 - 168)</td> <td>60.0 (12 - 264)</td> <td>0.760</td> </tr> </tbody> </table> <table border="1" data-bbox="427 861 1396 1050"> <thead> <tr> <th></th> <th colspan="3">Clinical Severity Scores (CSS)</th> <th></th> </tr> <tr> <th></th> <th>Group A $n = 35$</th> <th>Group B $n = 35$</th> <th>Group C $n = 34$</th> <th>p</th> </tr> </thead> <tbody> <tr> <td>CSS at 0 hours</td> <td>7.0 ± 1.7</td> <td>7.2 ± 1.9</td> <td>7.3 ± 1.7</td> <td>0.778</td> </tr> <tr> <td>CSS at 1 hour</td> <td>5.8 ± 1.9</td> <td>6.2 ± 1.8</td> <td>6.6 ± 2.0</td> <td>0.271</td> </tr> <tr> <td>CSS at 24 hours</td> <td>4.6 ± 1.7</td> <td>4.2 ± 1.3</td> <td>4.7 ± 1.1</td> <td>0.165</td> </tr> </tbody> </table> <p>Limitations:</p> <ul style="list-style-type: none"> Limited number of study participants No standardized dosage or volume of 7% inhaled saline Hypernatremia as side effect of inhaled saline treatment not evaluated <p>Additional Information</p> <ul style="list-style-type: none"> 1 mg/kg steroid were administered for 3 days to all patients with CSS ≥ 10 after 1 hour of initial treatment Two patients in group C subsequently withdrawn because of deteriorated clinical status. Patients discharged if CSS < 4, oxygen saturation $> 92\%$ in room air for 4 hours, and no feeding difficulty 		Length of Stay					Group A $n = 35$	Group B $n = 35$	Group C $n = 34$	p	LOS in hours (min - max)	72.0 (20 - 288)	64.0 (12 - 168)	60.0 (12 - 264)	0.760		Clinical Severity Scores (CSS)					Group A $n = 35$	Group B $n = 35$	Group C $n = 34$	p	CSS at 0 hours	7.0 ± 1.7	7.2 ± 1.9	7.3 ± 1.7	0.778	CSS at 1 hour	5.8 ± 1.9	6.2 ± 1.8	6.6 ± 2.0	0.271	CSS at 24 hours	4.6 ± 1.7	4.2 ± 1.3	4.7 ± 1.1	0.165
	Length of Stay																																								
	Group A $n = 35$	Group B $n = 35$	Group C $n = 34$	p																																					
LOS in hours (min - max)	72.0 (20 - 288)	64.0 (12 - 168)	60.0 (12 - 264)	0.760																																					
	Clinical Severity Scores (CSS)																																								
	Group A $n = 35$	Group B $n = 35$	Group C $n = 34$	p																																					
CSS at 0 hours	7.0 ± 1.7	7.2 ± 1.9	7.3 ± 1.7	0.778																																					
CSS at 1 hour	5.8 ± 1.9	6.2 ± 1.8	6.6 ± 2.0	0.271																																					
CSS at 24 hours	4.6 ± 1.7	4.2 ± 1.3	4.7 ± 1.1	0.165																																					

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The randomization of the given drug was performed according to the age, sex and CCS distributions of the patients with a computer program.
Allocation concealment (selection bias)	Unclear risk	No description of drug containers was given to know whether they were identical in appearance or had features that would allow differentiation between groups, though it does state that the treating providers did not know which drug was given
Blinding of participants and personnel (performance bias)	Unclear risk	Though this study states it is double-blinded, it does not explicitly state that participants and personnel are blinded to the treatment
Blinding of outcome assessment (detection bias)	Unclear risk	The outcome is assessed by researchers other than the primary providers treating the patients and administering treatment. Though the study states that it is double-blinded, it does not explicitly state that the outcome assessors are blinded to treatment.
Incomplete outcome data (attrition bias)	Low risk	Two patients in Group C withdrew due to deteriorated clinical status but were included in analysis and unlikely to affect outcome of study.
Selective reporting (reporting bias)	Low risk	All pre-determined outcomes were reported.
Other bias	Low risk	Study reports no conflict of interest or financial support.

Evidence Based Practice

Mahesh Kumar et al., 2013

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children < 2 years of age, admitted with first episode of lower respiratory tract infection during the winter months from October 2007 to March 2009. Setting: India, Bengalore, M S Ramaiah Medical College and Hospital, Department of Pediatrics Randomized into study: $N = 40$</p> <ul style="list-style-type: none"> • Group 1, 3% hypertonic saline (HS): $n = 20$ • Group 2, normal saline (NS): $n = 20$ <p>Completed Study: $N = 40$</p> <ul style="list-style-type: none"> • Group 1: $n = 20$ • Group 2: $n = 20$ <p>Gender, male ratio (as defined by researchers):</p> <ul style="list-style-type: none"> • All patients randomized into study: 1.6 : 1 <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (range):</p> <ul style="list-style-type: none"> • All patients randomized into study: 5.93 ± 3.83 (2 - 12 months) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children < 2 years of age • Admitted with first episode of lower respiratory tract infection • Present with wheeze and moderate respiratory distress • Clinical score between 4 and 8 <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Pre-existing cardiac disease • Previous wheezing episodes • Severe disease (clinical score > 8) • Need for mechanical ventilation <ul style="list-style-type: none"> ○ Oxygen saturation < 85% on room air ○ Cyanosis ○ Obtunded consciousness ○ Progression to respiratory failure <p>Power Analysis: Not reported</p>
<p>Interventions</p>	<p>Both: All patients received humidified oxygen, intravenous (IV) fluids, and a calculated dose of salbutamol (0.15 mg/kg/dose) for nebulization. The volume of nebulized saline was 3mL for both groups. Nebulized medications were administered every six hours until discharge, using identical nebulizer set-ups.</p> <ul style="list-style-type: none"> • Group 1: 3% saline (HS) • Group 2: normal saline (NS)
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Improvement in respiratory distress as indicated by clinical score* • Duration of hospital stay (LOS)* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Number of add-on nebulized treatments required • Failure rate, defined as children who showed a worsening of clinical scores during the course of stay <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> • Patients in the HS arm of the study demonstrated slightly more reduction in clinical severity (1.8 ± 0.83) than the NS arm (1.7 ± 0.86), $p = .712$

Evidence Based Practice

	<ul style="list-style-type: none"> • Patients in the HS arm had a 24% reduction in LOS, with mean LOS in the HS arm of 2.25 ± 0.89 days vs. in the NS arm of 2.88 ± 1.76 days, <i>MD</i> 0.63 ± 0.87, $p = .165$ • Patients in the HS arm had fewer add-on nebulized treatments (1.7 ± 1.75) vs the NS arm (2.4 ± 4.1) • Patients in the HS arm had no treatment failures, as opposed to four failures in the NS group, which was clinically significant $p = .03$ • All findings except the number of treatment failures were statistically insignificant. <p>Limitations:</p> <ul style="list-style-type: none"> • Small sample size • Younger age of the study population • Relatively low clinical scores
--	--

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomized into two groups using a computer generated random numbers. The eligible patients were recruited sequentially and randomized in a double-blind manner
Allocation concealment (selection bias)	Low risk	The eligible patients were recruited sequentially and randomized in a double-blind manner
Blinding of participants and personnel (performance bias)	Unclear risk	The authors did not report if there were any distinguishable differences between the HS and NS solutions including appearance, labels or packaging. Although the authors noted the randomization was done in a double-blind manner, no other information was reported regarding blinding of participants and personnel. While the risk of performance bias is likely low, the authors do not specifically speak to this concern. Insufficient information to permit judgment of low risk or high risk.
Blinding of outcome assessment (detection bias)	Unclear risk	Insufficient information to permit judgment of low risk or high risk.
Incomplete outcome data (attrition bias)	Low risk	All randomized subjects were included in analysis.
Selective reporting (reporting bias)	Low risk	The published report contains all expected outcomes
Other bias	Unclear risk	The authors did not disclose study funding or provide a declaration of competing interests.

Evidence Based Practice

Morikawa et al., 2018

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Infants < 12 months of age hospitalized for acute bronchiolitis due to respiratory syncytial virus (RSV) from November 2008 to March 2013 Setting: Two tertiary children's hospitals and three general hospitals in Tokyo, Japan Randomized into study: <i>N</i> = 128</p> <ul style="list-style-type: none"> • Group 1, 3% nebulized saline (HS): <i>n</i> = 63 • Group 2, 0.9% nebulized saline (NS): <i>n</i> = 65 <p>Completed Study: <i>N</i> = 128</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 63 • Group 2: <i>n</i> = 65 <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 36 (57%) • Group 2: <i>n</i> = 42 (65%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (SD):</p> <ul style="list-style-type: none"> • Group 1: 4.4 ± 3.1 • Group 2: 4.2 ± 3.0 <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Hospitalized infants < 12 months of age • Infants diagnosed with acute bronchiolitis due to RSV <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Infants with <ul style="list-style-type: none"> ○ pCO₂ >60 mm Hg ○ Oxygen saturation < 95% on oxygen ○ Episodes of apnea ○ Previous history of wheezing episodes ○ History of cerebral palsy, congenital heart disease, lung disease, muscular disorder, malformation syndrome, immune deficiency disorder ○ History of preterm birth (gestational age < 36 weeks) ○ Progressive respiratory failure requiring mechanical ventilation ○ Previous administration of palivizumab <p>Power Analysis: 80% (<i>p</i> = < 0.05, two-sided). The hazard ratio of the NS group to HS group was assumed to be 0.6. All analyses were based on intention-to-treat principle.</p>
<p>Interventions</p>	<p>Both: The patients in each group were treated four times daily during their hospital stay until they met discharge criteria (maintenance of axillary temperature below 37.5°C for 24 hours, no need for supplemental oxygen for 24 hours, adequate feeding defined as more than 100 mL/kg/day of milk or meals equal to or more than 70% of the preadmission volume as gauged by the physician and the parents). Additional nebulizations using the solutions were permitted. All nebulization therapies were delivered via standard oxygen-driven hospital nebulizers. The nebulizers used were the Cirrus™ nebulizer with a flow rate of 5 L/min, the PARI LC PLUS® with a flow rate of 5L/min, the Compressor Nebulizer NE-C29 with a flow rate of 10L/min, the Millicon Cube nebulizer with a flow rate of 10L/min, and the Millicon Cube nebulizer KN-80S with a flow rate of 10L/min. Oxygen was administered if the patient's oxygen saturation level remained below 95%. Once oxygenation of 94% was achieved, the oxygen supply was reduced, then stopped by the nurses. Additional therapies such as bronchodilators, intravenous fluids, deep nasal suction, and antibiotics were permitted at the discretion of the attending physicians. The use of steroids and/or theophylline was not allowed. Upon admission, Clinical Severity Scores (CSS), blood CO₂ levels, and a chest x-ray were obtained. RSV was diagnosed using one of three test kits. Nurses monitored the patients' oxygen saturation levels and for any adverse events occurring throughout the hospitalization. Body weight was recorded upon admission. Axillary temperature was</p>

Evidence Based Practice

	<p>obtained three times daily. Feeding status was monitored every morning. Follow-up was performed in the outpatient department on Day 7 after discharge.</p> <ul style="list-style-type: none"> • Group 1, 3% HS: Received 0.1 mL of 0.5% salbutamol in 2 mL of 3% HS • Group 2, 0.9% NS: Received nebulized 0.1 mL of 0.5% salbutamol in 2 mL of 0.9% NS
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of hospital stay* (defined as the time from admission until discharge criteria met) <p>Secondary outcome(s):</p> <ul style="list-style-type: none"> • Change in CSS between the time of admission and 72 hours later* • Duration of oxygen administration <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Adverse events defined in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> • One patient in the HS group received the treatment designed for the other group once and was included in the intention-to-treat group • Two patients who received hydrocortisone were included in the intention-to-treat group • Two patients were discharged before they fulfilled discharge criteria and were censored (lost to follow-up) at discharge. • The mean LOS was 4.71 ± 2.15 days for the study population (4.81 ± 2.14 days (HS); 4.61 ± 2.18 days (NS)) • There was not a significant difference ($p = .60$) between groups in overall LOS. • The mean duration of oxygen administration was not significant ($p = .55$) between groups (2.77 ± 2.68 days (HS); 2.50 ± 2.50 days (NS)) • The proportion of patients receiving oxygen was not significant ($p = .61$) between groups, consisting of 71.4% in the HS group and 75.4% in the NS group. • The CSS at baseline was not significant ($p = .56$) between groups (5.63 ± 2.09 (HS); 5.40 ± 2.47 (NS)) • Improvement in the CSS from baseline to 72 hours was not significant ($p = .91$) between groups (-3.63 ± 2.30 (HS); -3.58 ± 2.56 (NS)) • Two patients in the HS group required hospital readmittance (one for acute otitis media, the other for pneumonia) • No patients required mechanical ventilation following admission <p>Limitations:</p> <ul style="list-style-type: none"> • The study was open label presenting potential biases in LOS, the primary endpoint, and additional therapies. • Variability was reported in nebulizer types and administration methods • Lacked power to detect smaller effects than assumed ($HR = 0.6$) • Participants in the study were restricted to Japanese infants with RSV infection • • The study was not powered for secondary outcomes.

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Used data from the University Hospital Medical Information Network (UMIN) and the Internet Data and Information Center for Medical Research (INDICE).
Allocation concealment (selection bias)	Low risk	Dynamic (minimization) allocation was used to assign patients randomly to groups in a 1:1 ratio by stratification according to age (< 60 vs ≥ 60 days) and institute.
Blinding of participants and personnel (performance bias)	Low risk	The allocation status was disclosed at registration. The patients and treating physicians were not masked to assignment. The study reported the open-label nature as a potential for bias, though was able to predefine criteria which should not have been influenced due to lack of blinding.
Blinding of outcome assessment (detection bias)	Low risk	Biostatisticians were blinded to the allocation during the trial and analysis
Incomplete outcome data (attrition bias)	Low risk	Intention-to-treat analysis completed
Selective reporting (reporting bias)	Low risk	The study included reports of all outcomes
Other bias	Low risk	The study appears to be free of other risks of bias

Evidence Based Practice

Ojha et al., 2014

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children 6 weeks - 24 months with diagnosis of bronchiolitis Setting: Kathmandu, Nepal; hospital department of pediatrics, July 2012-August 2013 Randomized into study: <i>N</i> = 72</p> <ul style="list-style-type: none"> • Group 1, Nebulized 3% saline (Solution B): <i>n</i> = 36 • Group 2, Nebulized 0.9% saline (Solution A): <i>n</i> = 36 <p>Completed Study: <i>N</i> = 59</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 28 • Group 2: <i>n</i> = 31 <p>Gender, males: <i>N</i> = 53 (74%)</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = (%) not reported; see notes • Group 2: <i>n</i> = (%) not reported; see notes <p>Race / ethnicity or nationality:</p> <ul style="list-style-type: none"> • Not specified <p>Age: months, mean (+/- SD)</p> <ul style="list-style-type: none"> • Group 1: 8.61 (5.742) • Group 2: 8.51 (4.24) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children older than 6 weeks and below 24 months • Clinical presentation of bronchiolitis for the first time <ul style="list-style-type: none"> ○ Bronchiolitis was defined as the first episode of wheezing associated with tachypnea, increased respiratory effort, and an upper respiratory tract infection • Clinical scoring of respiratory distress ≥ 4 <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Previous episode of wheezing • Chronic cardiac and pulmonary disease • Immunodeficiency • Accompanying respiratory failure requiring mechanical ventilation • Inhalation of nebulized 3% hypertonic saline solution and salbutamol in the 12 hours before treatment • Premature infants born at less than 34 weeks gestation • Children with oxygen saturation < 85% on room air <p>Power Analysis: The sample size for this study was 72:36 in case and control group. This was calculated using PS-Power and Sample Size Calculator Version 3.0.43.</p>
<p>Interventions</p>	<p>Both:</p> <ul style="list-style-type: none"> • At least three nebulized saline treatments on each day of hospitalization, 8 hours apart • Clinical scoring tool was used 30 minutes before and immediately after treatment • Parameters measured using the clinical score: respiratory rate, wheezing, retractions, oxygen saturation <ul style="list-style-type: none"> • Group 1: 4ml nebulized 3% saline • Group 2: 4ml nebulized 0.9% saline
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of stay* • Need for supplemental oxygen (defined as oxygen saturation below 92% on room air) • Duration of supplemental oxygen • CSS improvement <p>*Outcomes of interest to the CMH CPG or CAT development team</p>

Notes	<p>Results:</p> <ul style="list-style-type: none"> • Length of stay <ul style="list-style-type: none"> ○ The difference in average duration of hospital stay was not statistically significant ($p = .86$) • Need for oxygen supplementation <ul style="list-style-type: none"> ○ Out of 72 children, 21 required oxygen supplementation. Twelve of these patients were in the 3% saline group and the remaining 9 were in the 0.9% saline group. • Duration of oxygen supplementation <ul style="list-style-type: none"> ○ The difference in mean duration of oxygen supplementation was not statistically significant ($p = .85$) • CSS improvement: <ul style="list-style-type: none"> ○ Both groups had a decrease in clinical severity score after commencement of the treatment; however, the decrease was not statistically significant according to the authors (p value not reported) ○ Children who received 3% saline and 0.9% saline took 36.79 (± 19.53) hours and 38.34 (± 26.67) hours respectively to have their clinical score fall below a score of 4; however, this difference was again not statistically significant ($p = .80$) <p>Limitations:</p> <ul style="list-style-type: none"> • Authors state that 53 (74%) of study participants were male but do not state how many were in each group • All participants received nebulized saline at least 3 times per day, more saline treatments could be done at the discretion of the treating physician • Authors report difficulty in asserting the diagnosis of bronchiolitis, as a diagnostic tool to identify the virus was not available • Difficult to distinguish between wheezing due to bronchiolitis vs. possible first episode of asthma
--------------	---

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number generator was used.
Allocation concealment (selection bias)	Low risk	Random numbers kept in a sealed envelope, labeling was done by sister who was not involved in patient care.
Blinding of participants and personnel (performance bias)	Low risk	Emergency physicians, house staff, nurses, study personnel, and patients were blinded to treatment allocation throughout the study.
Blinding of outcome assessment (detection bias)	Low risk	Study personnel were blinded to treatment throughout the study.
Incomplete outcome data (attrition bias)	High risk	Several children in both groups did not finish at parental request, either by leaving early against medical advice, being discharged at parent's request, or because parent wanted to discontinue study. The original power was for 36 participants in both groups, 5 were excluded in group 2 and 8 from group 1.
Selective reporting (reporting bias)	Low risk	Pre-specified outcomes reported as expected.
Other bias	Unclear risk	See limitations. In addition, this study does not address potential conflict of interest.

Evidence Based Practice

Pandit et al., 2013

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children between the ages of 2 to 12 months admitted with clinical diagnosis of acute bronchiolitis. Setting: Paediatrics Emergency at Government Multi Specialty Hospital (GMSH), Sector-16, Chandigarh, India. Randomized into study: $N = 100$</p> <ul style="list-style-type: none"> • Group 1, Group A: Hypertonic Saline: $n = 51$ • Group 2, Group B: Normal Saline: $n = 49$ <p>Completed Study: $N = 100$</p> <ul style="list-style-type: none"> • Group 1: $n = 51$ • Group 2: $n = 49$ <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Not detailed in article. Noted in results section that groups had comparable demographic data. <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not detailed in article. Noted in results section that groups had comparable demographic data. <p>Age, mean/median in months/years, (range/IQR): not detailed in article. Noted in results section that groups had comparable demographic data.</p> <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Children ages 2 to 12 months • Clinical diagnosis of acute bronchiolitis (short history of cough with or without fever of less than seven days duration and wheezing on examination and with the first attack of wheezing) <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Patient with recurrent episodes of wheezing, one or more episodes of respiratory distress in the past. • Patients with family history of asthma, atopy • Presence of congenital heart disease • History of prematurity or mechanical ventilation in newborn period • Very sick patients with shock, seizures, heart rate > 180/minute and adjudged to be in incipient respiratory failure • Grade III and IV PEM • Consolidation lung on x-ray chest • No child included in the study twice <p>Power Analysis: The calculated sample size was 100 for 80% power and a 95% confidence interval</p>
<p>Interventions</p>	<p>Both: Nebulization given three times upon admission with an interval of one hour between two nebulization, and every 6 hours thereafter Assessment of respiratory rate, respiratory distress assessment instrument (RDAI) score, heart rate, oxygen saturation was done on admission before the nebulization and half an hour after third nebulization. Nebulization given every 6 hours with respective saline and adrenaline daily until discharge.</p> <ul style="list-style-type: none"> • Group 1: 4mL of 3% hypertonic saline and 1mL of 1:1,000 adrenaline was given as nebulization with oxygen flow of 6-8 L/minute. • Group 2: 4mL of normal saline (0.9%) and 1mL of 1:1,000 adrenaline was given as nebulization.
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of stay* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Improvement in RDAI score • Respiratory rate

Evidence Based Practice

	<ul style="list-style-type: none"> • Oxygen saturation • Heart rate • Number of add on treatments • Adverse events* <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
Notes	<p>Results:</p> <ul style="list-style-type: none"> • Found no significant difference between the two groups in relation to length of stay ($p = .67$). • Length of stay significantly higher in patients who received add on treatments ($p < .05$) • Secondary outcomes <ul style="list-style-type: none"> ○ No significant difference in clinical parameters between group 1 and group 2 on day 1 and day 2 of admission. ($p > .05$) ○ Significant improvement in clinical parameters from pre to post nebulization within both groups on day 1 and day 2 of admission. ($p < 0.05$) • Adverse events <ul style="list-style-type: none"> ○ Side effects (vomiting, diarrhea) noted in 4% of participants; all enrolled in group 2. ○ No adverse effects such as tremors or paleness in any participant. <p>Limitations:</p> <ul style="list-style-type: none"> • Non-blinded study design; introducing some bias during evaluation. • Only included hospitalized children ≤ 12 months of age • Enrolled based upon clinical diagnosis and not confirmed by viral studies • Exact duration of hypertonic saline effect and its continuing impact on clinical parameter is unknown

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Utilized a computer generated program for random assignment between groups
Allocation concealment (selection bias)	Unclear risk	Concealed in an opaque envelope
Blinding of participants and personnel (performance bias)	High risk	Non-blinded study. Staff were aware of participants' treatment groups.
Blinding of outcome assessment (detection bias)	High risk	Non-blinded study design; assessment could be influenced by knowing treatment prescribed
Incomplete outcome data (attrition bias)	Low risk	All participants completed study.
Selective reporting (reporting bias)	Low risk	All results were reported out.
Other bias	Low risk	Reported no conflicts of interest, no financial sponsorships

Evidence Based Practice

Sharma et al., 2013

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Hospitalized children (age 1 - 24 months) with acute bronchiolitis of moderate severity Setting: Tertiary care teaching hospital. No additional setting information was provided. Randomized into study: $N = 250$</p> <ul style="list-style-type: none"> • Group 1, Hypertonic Saline (HS) Group: $n = 125$ • Group 2, Normal Saline (NS) Group: $n = 125$ <p>Completed Study: $N = 248$</p> <ul style="list-style-type: none"> • Group 1: $n = 125$ • Group 2: $n = 123$ <p>Gender, % males:</p> <ul style="list-style-type: none"> • Group 1: $n = 77.6\%$ • Group 2: $n = 74.8\%$ <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months (SD)</p> <ul style="list-style-type: none"> • Group 1: 4.93 ± 4.31 • Group 2: 4.18 ± 4.24 <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Hospitalized infants and children aged 1 to 24 months. • Clinical presentation of viral bronchiolitis of moderate severity, with a clinical severity score of 3-6. <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Obtunded consciousness • Cardiac disease • Chronic respiratory disease • Previous wheezing episode • Progressive respiratory distress requiring respiratory support other than supplemental oxygen • Received nebulized hypertonic saline within the previous 12 hours <p>Power Analysis: Not reported</p>
<p>Interventions</p>	<p>Both: Both groups received 2.5 mg salbutamol. All medications were administered by nebulizer every 4 hours, six times daily till the patient was ready for discharge, using a conventional jet nebulizer, tight fitting face mask, and oxygen flow rate of 7L/minute.</p> <ul style="list-style-type: none"> • Group 1: 4 mL 3% HS • Group 2: 4 mL 0.9% NS
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • To compare the length of hospital stay (time taken to reach clinical severity score <3).* <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • To compare the improvement in clinical severity scores in hospitalized children with acute bronchiolitis nebulized with 3% HS and NS.* <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CPG or CAT development team</p>
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> • There was no significant difference in Clinical Severity (CS) score at enrollment and at reassessment every 12 hours until discharge (values not given, shown in graph as median CSS over time after admission)

Evidence Based Practice

	<ul style="list-style-type: none"> There was also no difference in mean length of hospital stay in hours for the group receiving HS (63.51 ± 21.27) vs. the group receiving NS (63.93 ± 22.43), $p = .878$. <p>Limitations:</p> <ul style="list-style-type: none"> The authors noted the median CS score at time 0 was based on 125 subjects, whereas the data at 132 hours was only based on two patients (due to timing of hospital discharge) The study was not powered for secondary outcomes.
--	---

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated random numbers were used for enrolment in consecutive manner and patients were randomly assigned to a treatment arm
Allocation concealment (selection bias)	Low risk	HS and NS solutions had no detectable differences in color, smell, or other physical properties. The combination code of the therapeutic package was not available to the investigator or treating medical staff (only the statistician). Solutions were administered to patients using identical equipment, method and interval
Blinding of participants and personnel (performance bias)	Low risk	All participants and study personnel were appropriately blinded and it is unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias)	Low risk	Blinding of outcome assessment was ensured. Investigators performing assessments were unaware of treatment arm assignment
Incomplete outcome data (attrition bias)	Low risk	125 participants were assigned to the NS group and 123 were analyzed. The authors do not address the two patients that were not included in the analysis. However, the required sample size in each arm was 113 patients and the difference in sample size between the HS and NS groups was negligible, making it unlikely that the two missing patients are enough to introduce clinically relevant bias
Selective reporting (reporting bias)	Low risk	Published reports include the expected outcomes.
Other bias	Low risk	They reported there was no funding for this study and no competing interests.

Evidence Based Practice

Silver et al., 2015

Methods	Randomized Control Trial																		
<p>Participants</p>	<p>Participants: Patients < 12 months of age hospitalized with bronchiolitis Setting: Urban tertiary care children's hospital, November 2011 to June 2014, United States Randomized into study: <i>N</i> = 227</p> <ul style="list-style-type: none"> • Group 1, nebulized 3% hypertonic saline (HS): <i>n</i> = 113 • Group 2, nebulized 0.9% normal saline (NS) <i>n</i> = 114 <p>Completed Study: <i>N</i> = 190</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 93 • Group 2: <i>n</i> = 97 <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: <i>n</i> = 62 (67%) • Group 2: <i>n</i> = 60 (62%) <p>Race / ethnicity or nationality (as defined by researchers), <i>n</i> (%):</p> <table border="1" data-bbox="423 758 979 936"> <thead> <tr> <th></th> <th>HS</th> <th>NS</th> </tr> </thead> <tbody> <tr> <td>Black</td> <td>24 (26)</td> <td>35 (36)</td> </tr> <tr> <td>White</td> <td>17 (18)</td> <td>17 (18)</td> </tr> <tr> <td>Other</td> <td>48 (52)</td> <td>41 (42)</td> </tr> <tr> <td>Missing</td> <td>4 (4)</td> <td>4 (4)</td> </tr> <tr> <td>Hispanic ethnicity</td> <td>71 (76)</td> <td>71 (73)</td> </tr> </tbody> </table> <p>Age, mean in months, (SD)</p> <ul style="list-style-type: none"> • Group 1: 3.9 ± 3.0 • Group 2: 4.4 ± 3.0 <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Physician diagnosis of bronchiolitis • < 12 months old <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Treatment of asthma (corticosteroids or bronchodilators) • Chronic cardiopulmonary disease such as bronchopulmonary dysplasia, cystic fibrosis • Previous nebulized hypertonic saline < 12 hours before presentation • Non-English, non-Spanish speaker • Enrollment assessment > 12 hours after admission • Patients previously enrolled within 72 hours of presentation <p>Power Analysis: 105 subjects were needed in each arm to identify a 0.6 day change in length of stay, with 80% power with a 2-tailed test. Alpha = 0.05.</p>		HS	NS	Black	24 (26)	35 (36)	White	17 (18)	17 (18)	Other	48 (52)	41 (42)	Missing	4 (4)	4 (4)	Hispanic ethnicity	71 (76)	71 (73)
	HS	NS																	
Black	24 (26)	35 (36)																	
White	17 (18)	17 (18)																	
Other	48 (52)	41 (42)																	
Missing	4 (4)	4 (4)																	
Hispanic ethnicity	71 (76)	71 (73)																	
<p>Interventions</p>	<p>Both: In addition to treatment every 4 hours, all patients could receive study treatment every 2 hours prn with a maximum of 2 PRN doses per 24 hour period</p> <ul style="list-style-type: none"> • Group 1: 4 mL of nebulized 3% HS every 4 hours from enrollment until hospital discharge • Group 2: 4 mL of NS every 4 hours from enrollment until hospital discharge 																		
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of stay defined as the time from the first study treatment to the time of hospital discharge or meeting discharge criteria <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Adverse events • Seven-day readmission rates • Clinical worsening- transfer to PICU or bronchospasm within 30 minutes of a nebulized study treatment, as indicated by a RDAI score worsening by >= to 4 <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Not reported 																		

Evidence Based Practice

	*Outcomes of interest to the CMH CPG or CAT development team
Notes	<p>Results</p> <ul style="list-style-type: none"> No difference in median (IQR) length of stay between the group receiving HS (2.1 days, (1.2 - 4.6)) and the group receiving NS (2.1 days, (1.2 - 3.8)), $p = .73$. No difference in total adverse events between the group receiving HS, $n = 14$ (15%) and the group receiving NS, $n = 12$ (12%), $p = .67$. No difference in readmissions between the group receiving HS, $n = 4$ (4%) and the group receiving NS, $n = 3$ (3%), $p = .77$. No difference in clinical worsening between the group receiving HS, $n = 10$ (9%) and the group receiving NS, $n = 9$ (8%), $p = .97$. <p>Limitations</p> <ul style="list-style-type: none"> Use of NS as control instead of placebo Single-center study raises question of generalizability of results Enrollment within 12 hour window of time of admission could influence duration of patients' participation in study No minimum severity score for eligibility Variability in approach to nebulized treatment administration in infants resisting and crying infants The study was not powered for secondary outcomes. <p>Additional Information</p> <ul style="list-style-type: none"> Patients with prematurity were included in both treatment and control arms Exit criteria: <ul style="list-style-type: none"> Respiratory Distress Assessment Instrument (RDAI) before and 30 minutes after the first study treatment as a safety measure. An increase of ≥ 4 points the patient received a bronchodilator and withdrawn from the study ($n = 1$) Provider initiated bronchodilators or corticosteroids ($n = 8$) Transfer to PICU Parent or guardian request

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated block randomization
Allocation concealment (selection bias)	Low risk	Allocation concealed and administered by Investigational Drug Services
Blinding of participants and personnel (performance bias)	Low risk	Study medications were indistinguishable from one another
Blinding of outcome assessment (detection bias)	Low risk	Outcome assessors were blinded to the treatment given
Incomplete outcome data (attrition bias)	High risk	Thirty-seven subjects did not complete the study, 20 from the treatment arm and 17 from the control arm. Only per-protocol analysis was completed. For the per protocol analysis, they did not meet power.
Selective reporting (reporting bias)	Low risk	All pre-identified outcomes were reported
Other bias	Low risk	No potential conflicts of interest, funding, or financial relationships reported

Evidence Based Practice

Teunissen et al., 2014

Methods	Randomized Control Trial
<p>Participants</p>	<p>Participants: Children, 0 - 24 months, admitted for mild to severe viral bronchiolitis with a Wang score of >2, from November 2009 to May 2011 Setting: Eleven general hospitals and one tertiary medical center in the Netherlands Randomized into study: N = 292</p> <ul style="list-style-type: none"> • Group 1, 3% hypertonic saline (3% HS): n = 97 • Group 2, 6% hypertonic saline (6% HS): n = 102 • Group 3, Control (0.9% NS): n = 93 <p>Completed Study: N = 247</p> <ul style="list-style-type: none"> • Group 1: n = 80 • Group 2: n = 84 • Group 3: n = 83 <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: n = 44 (52.4%) • Group 2: n = 48 (57.8%) • Group 3: n = 49 (61.3%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • Not reported <p>Age, mean in months, (IQR):</p> <ul style="list-style-type: none"> • Group 1: 3.6 (5.2) • Group 2: 3.4 (3.8) • Group 3: 3.5 (5.0) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Hospitalized children 0 - 24 months of age • Diagnosis of mild to severe viral bronchiolitis, by nasal swab • Wang score of > 2 at presentation <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Wang score improvement of at least 2 points after 2.5 mg salbutamol inhalation • Hemodynamically important congenital heart disease • Chronic pre-existing lung disease • T-cell immunodeficiency • Treatment with corticosteroids • Previous wheezing • Allergy (food) or eczema <p>Power Analysis: 65 patients per trial arm required for the current study to achieve a power of 90% (p <.05)</p>
<p>Interventions</p>	<p>Both: The patients in each group were treated every 8 hours until discharge. Treatment given with a constant oxygen flow of 6–8 L/min from a wall outlet in combination with a HOT Top Plus Nebulizer (Intersurgical, Uden, The Netherlands), Mass Median Aerodynamic Diameter (MMAD) 4 mm, via a tight-fitting face mask and were administered until empty. Evaluation twice daily by pediatrician on duty, based on physical examination, Wang score, heart rate, saturation, respiratory rate, need for supplemental oxygen, and tube feeding. Supplemental oxygen was initiated with a room air saturation of 93%, or lower, during > 10 min or acute desaturation of <85%. This was stopped when saturation was consistently >93%. The indication for starting and stopping tube feeding was a minimal intake calculated as 75% of normal intake. Fluid loss because of dehydration or diarrhea was compensated by the addition of lost fluid to the minimal intake. Additional medication and other supportive care were given according to hospital guidelines. All additional medication, time and quantity of supplemental oxygen and tube feeding were recorded in the case record form. Protocol-defined discharge criteria included no need for supplemental oxygen, tube-feeding or intravenous fluids, according to the responsible pediatrician.</p>

Evidence Based Practice

	<ul style="list-style-type: none"> • Group 1: 3% HS: Received 2.5 mg Salbutamol and 3% sodium chloride, total volume of 4ml • Group 2: 6% HS: Received 2.5 mg Salbutamol and 6% sodium chloride, total volume of 4 ml • Group 3: 0.9% NS: Received 2.5 mg Salbutamol and 0.9% sodium chloride, total volume of 4ml 										
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Length of hospital stay (LOS)* (calculated as the number of hours between the first dose of study medication and the clinical decision to discharge) <p>Secondary outcome(s)</p> <ul style="list-style-type: none"> • Transfer to Pediatric Intensive Care Unit (PICU) because of respiratory insufficiency, need and duration of supplemental oxygen or tube feeding. • Wang Clinical Severity Score (CSS) <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Registration of adverse events <p>*Outcomes of interest to the CMH CPG or CAT development team</p>										
<p>Notes</p>	<p>Results:</p> <ul style="list-style-type: none"> • A substantial number of adverse effects were noted in all treatment groups, withdrawal because of adverse events did not differ between groups ($p = .59$) • No significant difference ($p = .26$) between groups in overall LOS • No significant difference ($p = .7$) between groups in supplemental oxygen need, median duration of 54, 54, and 40 hours • Wang CSS improved at discharge for all groups without significant difference between groups ($p = .8$) • Cough occurred significantly more in both HS groups ($p = .03$) <p>Length of Hospital Stay</p> <table border="1" data-bbox="427 1129 1170 1276"> <thead> <tr> <th>Timeframe</th> <th>3% HS Group (n = 84)</th> <th>6% HS Group (n = 83)</th> <th>NS Group (n = 80)</th> <th>p - value</th> </tr> </thead> <tbody> <tr> <td>Hours, median (IQR)</td> <td>69 (57)</td> <td>70 (69)</td> <td>53 (53)</td> <td>.29</td> </tr> </tbody> </table> <p>Limitations:</p> <ul style="list-style-type: none"> • Participants in the study restricted to children in the Netherlands with viral bronchiolitis • Exclusion of children with a rapid response to single dose salbutamol; 14% screened for inclusion had to be excluded due to positive response to salbutamol • The study not designed to examine subgroups with different disease severity • Study only considered nebulized therapy, not non-nebulized therapy • The study was not powered for secondary outcomes. 	Timeframe	3% HS Group (n = 84)	6% HS Group (n = 83)	NS Group (n = 80)	p - value	Hours, median (IQR)	69 (57)	70 (69)	53 (53)	.29
Timeframe	3% HS Group (n = 84)	6% HS Group (n = 83)	NS Group (n = 80)	p - value							
Hours, median (IQR)	69 (57)	70 (69)	53 (53)	.29							

Evidence Based Practice

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Nico Oldenhof (VieCuri Medical Centre, Venlo, The Netherlands) created the randomization procedure. Randomization was done per center and clustered in blocks of six patients.
Allocation concealment (selection bias)	Low risk	Each patient received a consecutively randomized number that corresponded to identical 20 mL vials, which contained the different sodium chloride solutions
Blinding of participants and personnel (performance bias)	Low risk	All participants, care givers and medical staff were blinded to the composition of the study solutions, which were identical in vial packaging, color, smell and other physical characteristics
Blinding of outcome assessment (detection bias)	Unclear risk	Before the start of the study all participating medical staff were trained how to evaluate the patients and classify the Wang clinical severity scoring system in order to improve inter-observer agreement
Incomplete outcome data (attrition bias)	Low risk	Analyses were done according to the intention-to-treat and per protocol principles. Differences between included and excluded patients, with respect to patient characteristics, were evaluated by means of independent t-test (age) and Chi-squared test (sex and intervention).
Selective reporting (reporting bias)	Low risk	The study included reports of all outcomes
Other bias	Low risk	Financial support disclosed and conflicts of interest disclosed

Evidence Based Practice

Wu et al., 2014

Methods	Randomized Control Trial																		
<p>Participants</p>	<p>Participants: Children younger than 24 months with primary diagnosis of viral bronchiolitis during bronchiolitis season. Setting: Emergency department at 2 tertiary free-standing urban children's hospitals in California. Randomized into study: $N = 447$</p> <ul style="list-style-type: none"> • Group 1, 0.9% Normal Saline (NS): $n = 216$ • Group 2, 3% Hypertonic Saline (HS): $n = 231$ <p>Completed Study: $N = 394$</p> <ul style="list-style-type: none"> • Group 1: $n = 190$ • Group 2: $n = 204$ <p>Gender, males (as defined by researchers):</p> <ul style="list-style-type: none"> • Group 1: $n = 118$ (54.6%) • Group 2: $n = 136$ (58.9%) <p>Race / ethnicity:</p> <table border="1" data-bbox="423 787 1052 993"> <thead> <tr> <th></th> <th>Group 1 n (%)</th> <th>Group 2 n (%)</th> </tr> </thead> <tbody> <tr> <td>White</td> <td>21 (9.7)</td> <td>13 (5.6)</td> </tr> <tr> <td>African American</td> <td>25 (11.6)</td> <td>43 (18.6)</td> </tr> <tr> <td>Latino/Hispanic</td> <td>142 (65.7)</td> <td>147 (63.6)</td> </tr> <tr> <td>Asian</td> <td>7 (3.2)</td> <td>10 (4.3)</td> </tr> <tr> <td>Other</td> <td>21 (9.7)</td> <td>18 (7.8)</td> </tr> </tbody> </table> <p>Age, mean (SD) in months:</p> <ul style="list-style-type: none"> • Group 1: 6.40 (5.33) • Group 2: 6.57 (5.17) <p>Inclusion Criteria:</p> <ul style="list-style-type: none"> • Younger than 24 months with a primary diagnosis of viral bronchiolitis during bronchiolitis season (November - April) <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> • Prior illness with wheezing or bronchodilator use • Premature (gestational age, <34 weeks) • Cyanotic congenital heart disease • Chronic lung disease • Tracheostomy <p>Power Analysis: For length of stay, 124 patients in each arm would yield 80% power to detect a significant difference ($p < .05$)</p>		Group 1 n (%)	Group 2 n (%)	White	21 (9.7)	13 (5.6)	African American	25 (11.6)	43 (18.6)	Latino/Hispanic	142 (65.7)	147 (63.6)	Asian	7 (3.2)	10 (4.3)	Other	21 (9.7)	18 (7.8)
	Group 1 n (%)	Group 2 n (%)																	
White	21 (9.7)	13 (5.6)																	
African American	25 (11.6)	43 (18.6)																	
Latino/Hispanic	142 (65.7)	147 (63.6)																	
Asian	7 (3.2)	10 (4.3)																	
Other	21 (9.7)	18 (7.8)																	
<p>Interventions</p>	<p>Both: Patients in the emergency department received 2.5 mg of nebulized albuterol sulfate, followed by 4 mL of nebulized HS or NS. ED physicians could order up to 2 additional treatments every 20 minutes. Other care given at discretion of physician. Admitted patients continued receiving nebulized HS or NS with albuterol every 8 hours until discharge.</p> <ul style="list-style-type: none"> • Group 1: 4 mL of NS • Group 2: 4 mL of HS 																		
<p>Outcomes</p>	<p>Primary outcome(s):</p> <ul style="list-style-type: none"> • Admission rate • Length of stay* • Respiratory Distress Assessment Instrument (RDAI) score • Supplemental Therapies <p>Safety outcome(s):</p> <ul style="list-style-type: none"> • Adverse Events* <p>*Outcomes of interest to the CMH CPG or CAT development team</p>																		

Evidence Based Practice

Notes	<p>Results:</p> <ul style="list-style-type: none"> • Hypertonic saline given to children with bronchiolitis in the ED decreased hospital admissions. • No significant difference in RDAI score or LOS between groups. • Found a significant difference between sites for mean LOS. • Found no difference between the mean (SD) Respiratory Assessment Change Score for the NS and HS groups. Found no significant change when adjusting for the baseline RDAI score. • No significant difference was found in supplemental treatment use between groups. • Six patients in the NS group and 4 in the HS group required transfer to the PICU or NICU. <p>Limitations:</p> <ul style="list-style-type: none"> • Failure to achieve planned sample size of 350 in each arm • Only 145 patients underwent analysis for LOS, which is underpowered to detect differences in LOS of < 1 day • The study was not powered for secondary outcomes.
--------------	---

Risk of bias table

Bias	Judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Patients were allocated by simple randomization to the HS or the NS group by the investigational pharmacy, using a computer-generated random number table stratified by site.
Allocation concealment (selection bias)	Low risk	Families, clinical staff, and study personnel were blinded to treatment allocation.
Blinding of participants and personnel (performance bias)	Low risk	Study medication was identical in color, odor, and labeling.
Blinding of outcome assessment (detection bias)	Low risk	Patients enrolled in the ED received 2.5 mg of nebulized albuterol sulfate, followed by 4 mL of normal saline or hypertonic saline via a small-volume wall nebulizer. The ED physicians could order 2 additional treatments every 20 minutes to a maximum of 3 inhaled doses.
Incomplete outcome data (attrition bias)	Low risk	No missing outcome data.
Selective reporting (reporting bias)	Low risk	Reports include all expected outcome data.
Other bias	Low risk	No conflicts of interest were reported. Funding was provided by a grant but the funding sources had no role in the study.

References

- Alatwani, S. H., Almusway, Z. M., & Alwaeli, S. H. H. (2021). Application of nebulized 3% hypertonic saline in comparison to conventional therapy for treatment of bronchiolitis and effective on hospital duration of patient [Article]. *Current Pediatric Research*, 25(11), 1093-1098.
<https://www.embase.com/search/results?subaction=viewrecord&id=L2020649899&from=export>
- Angoulvant, F., Bellêtre, X., Milcent, K., Teglas, J. P., Claudet, I., Le Guen, C. G., De Pontual, L., Minodier, P., Dubos, F., Brouard, J., Soussan-Banini, V., Degas-Bussiere, V., Gatin, A., Schweitzer, C., Epaud, R., Ryckewaert, A., Cros, P., Marot, Y., Flahaut, P., . . . Gajdos, V. (2017). Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: A randomized clinical trial [Article]. *JAMA Pediatrics*, 171(8). <https://doi.org/10.1001/jamapediatrics.2017.1333>
- Brooks, C. G., Harrison, W. N., & Ralston, S. L. (2016). Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: A reanalysis of 2 meta-analyses [Article]. *JAMA Pediatrics*, 170(6), 577-584.
<https://doi.org/10.1001/jamapediatrics.2016.0079>
- Canty, W. B., & Colomb-Lippa, D. (2014). Using hypertonic saline to manage bronchiolitis in infants [Article]. *JAAPA : official journal of the American Academy of Physician Assistants*, 27(7), 45-49.
<https://doi.org/10.1097/01.JAA.0000450814.59448.cc>
- Everard, M. L., Hind, D., Ugonna, K., Freeman, J., Bradburn, M., Cooper, C. L., Cross, E., Maguire, C., Cantrill, H., Alexander, J., McNamara, P. S., & Team, S. S. (2014). SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. *Thorax*, 69(12), 1105-1112.
<https://doi.org/10.1136/thoraxjnl-2014-205953>
- Everard, M. L., Hind, D., Ugonna, K., Freeman, J., Bradburn, M., Dixon, S., Maguire, C., Cantrill, H., Alexander, J., Lenney, W., McNamara, P., Elphick, H., Chetcuti, P. A. J., Moya, E. F., Powell, C., Garside, J. P., Chadha, L. K., Kurian, M., Lehal, R. S., . . . Cross, E. (2015). Saline in acute bronchiolitis RCT and economic evaluation: Hypertonic saline in acute bronchiolitis – Randomised controlled trial and systematic review [Article]. *Health Technology Assessment*, 19(66), 1-130. <https://doi.org/10.3310/hta19660>
- Faten, T., Sana, A., Imen, B. H., Samia, H., Ines, B., Bechir, Z., & Khadija, B. (2015). A randomized, controlled trial of nebulized 5% hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis [Article]. *Tunisie Medicale*, 92(11), 674-677.
<https://www.embase.com/search/results?subaction=viewrecord&id=L602890241&from=export>
- Flores-González, J. C., Valladares, C. M., Yun Castilla, C., Mayordomo-Colunga, J., Quesada, S. P., Martín Delgado, C. M., Goñi-Orayen, C., Fernández Carrión, F., Veiga, A. M., Olmedilla-Jodar, M., Alcaraz Romero, A. J., Eizmendi-Bereciartua, M., Gutierrez, C. S., Luján, E. A., Navarro-Mingorance, Á., & Jordán, I. (2019). Association of Fluid Overload with Clinical Outcomes in Critically Ill Children with Bronchiolitis: Bronquiolitis en la Unidad de Cuidados Intensivos Pediátricos (BRUCIP) Study*. *Pediatr. Crit. Care Med.*, 20(3), E130-E136.
<https://doi.org/doi:10.1097/PCC.0000000000001841>
- Frassanito, A., Nenna, R., Arima, S., Petrarca, L., Pierangeli, A., Scagnolari, C., Di Mattia, G., Mancino, E., Matera, L., Porta, D., Rusconi, F., & Midulla, F. (2022). Modifiable environmental factors predispose term infants to bronchiolitis but bronchiolitis itself predisposes to respiratory sequelae [Article]. *Pediatric Pulmonology*, 57(3), 640-647. <https://doi.org/10.1002/ppul.25794>
- Heikkilä, P., Mecklin, M., & Korppi, M. (2018). The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis: a decision analysis [Article]. *World Journal of Pediatrics*, 14(1), 26-34.
<https://doi.org/10.1007/s12519-017-0112-8>
- Hmar, L., Brahmacharimayum, S., Golmei, N., Moirangthem, M., & Chongtham, S. (2021). Comparison of 3% saline versus normal saline as a diluent for nebulization in hospitalized children with acute bronchiolitis: A randomized clinical trial [Article]. *JMS - Journal of Medical Society*, 34(2), 86-90. https://doi.org/10.4103/jms.jms_43_20
- Jacobs, J. D., Foster, M., Wan, J., & Pershad, J. (2014). 7% hypertonic saline in acute bronchiolitis: A randomized controlled trial [Article]. *Pediatrics*, 133(1), e8-e13. <https://doi.org/10.1542/peds.2013-1646>
- Jaquet-Pilloud, R., Verga, M. E., Russo, M., Gehri, M., & Pauchard, J. Y. (2020). Nebulised hypertonic saline in moderate-to-severe bronchiolitis: A randomised clinical trial [Article]. *Archives of Disease in Childhood*, 105(3), 236-240. <https://doi.org/10.1136/archdischild-2019-317160>
- Köse, S., Şehriyaroğlu, A., Esen, F., Özdemir, A., Kardaş, Z., Altuğ, U., Karakuş, E., Özcan, A., Kisaarslan, A. F., Elmali, F., Torun, Y. A., & Köse, M. (2016). Comparing the efficacy of 7%, 3% and 0.9% saline in moderate to severe bronchiolitis in infants [Article]. *Balkan Medical Journal*, 33(2), 193-197.
<https://doi.org/10.5152/balkanmedj.2016.16840>
- Li, G., & Zhao, J. (2014). Effectiveness of inhaled hypertonic saline in children with bronchiolitis [Article]. *Zhonghua er ke za zhi. Chinese journal of pediatrics*, 52(8), 607-610.
<https://www.embase.com/search/results?subaction=viewrecord&id=L604744703&from=export>

Evidence Based Practice

- Lin, J., Zhang, Y., Song, A., Ying, L., & Dai, J. (2022). Exploring the appropriate dose of nebulized hypertonic saline for bronchiolitis: a dose-response meta-analysis [Article]. *Journal of investigative medicine : the official publication of the American Federation for Clinical Research*, 70(1), 46-54. <https://doi.org/10.1136/jim-2021-001947>
- Morikawa, Y., Miura, M., Furuhashi, M. Y., Morino, S., Omori, T., Otsuka, M., ... & Tokyo Pediatric Clinical Research Network. (2018). Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: a multicenter randomized controlled trial. *Pediatric Pulmonology*, 53(3), 358-365.
- Nenna, G., & Costantino, G. (2013). 0.9 % saline vs 6 % HES 130/0.4 for fluid resuscitation in critically ill patients. *Intern Emerg Med*, 8(4), 347-348. <https://doi.org/10.1007/s11739-013-0938-6>
- Ojha, A. R., Mathema, S., Sah, S., & Aryal, U. R. (2014). A comparative study on use of 3% saline versus 0.9% saline nebulization in children with bronchiolitis [Article]. *Journal of Nepal Health Research Council*, 12(26), 39-43. <https://www.embase.com/search/results?subaction=viewrecord&id=L606350417&from=export>
- Ralston, S., Hill, V., & Martinez, M. (2010). Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis. *Pediatrics*, 126(3), e520-e525.
- Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., Gadomski, A. M., Johnson, D. W., Light, M. J., Maraga, N. F., Mendonca, E. A., Phelan, K. J., Zorc, J. J., Stanko-Lopp, D., Brown, M. A., Nathanson, I., Rosenblum, E., Sayles, S., 3rd, Hernandez-Cancio, S., & American Academy of, P. (2014). Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*, 134(5), e1474-1502. <https://doi.org/10.1542/peds.2014-2742>
- Shahid, S., Javeed, A., & Wamiq, S. (2022). Outcome of Hypertonic Saline Versus Normal Saline in Children with Acute Bronchiolitis [Article]. *Pakistan Journal of Medical and Health Sciences*, 16(9), 278-279. <https://doi.org/10.53350/pjmhs22169278>
- Sharma, B. S., Gupta, M. K., & Rafik, S. P. (2013). Hypertonic (3%) saline Vs 0.9% saline nebulization for acute viral bronchiolitis: A randomized controlled trial [Article]. *Indian Pediatrics*, 50(8), 743-747. <https://doi.org/10.1007/s13312-013-0216-8>
- Silver, A. H., Esteban-Cruciani, N., Azzarone, G., Douglas, L. C., Lee, D. S., Liewehr, S., Nazif, J. M., Agalliu, I., Villegas, S., Rhim, H. J. H., Rinke, M. L., & O'Connor, K. (2015). 3% Hypertonic saline versus normal saline in inpatient bronchiolitis: A randomized controlled trial [Article]. *Pediatrics*, 136(6), 1036-1043. <https://doi.org/10.1542/peds.2015-1037>
- Tinsa, F., Abdelkafi, S., Bel Haj, I., Hamouda, S., Brini, I., Zouari, B., & Boussetta, K. (2014). A randomized, controlled trial of nebulized 5% hypertonic saline and mixed 5% hypertonic saline with epinephrine in bronchiolitis. *Tunis Med*, 92(11), 674-677. <https://www.ncbi.nlm.nih.gov/pubmed/25867149>
- Wu, S., Baker, C., Lang, M. E., Schragger, S. M., Liley, F. F., Papa, C., Mira, V., Balkian, A., & Mason, W. H. (2014). Nebulized hypertonic saline for bronchiolitis: A randomized clinical trial [Article]. *JAMA Pediatrics*, 168(7), 657-663. <https://doi.org/10.1001/jamapediatrics.2014.301>
- Yu, J. F., Zhang, Y., Liu, Z. B., Wang, J., & Bai, L. P. (2022). 3% nebulized hypertonic saline versus normal saline for infants with acute bronchiolitis: A systematic review and meta-analysis of randomized controlled trials [Article]. *Medicine (United States)*, 101(43), E31270. <https://doi.org/10.1097/MD.00000000000031270>
- Zhang, L., Gunther, C. B., Franco, O. S., & Klassen, T. P. (2018). Impact of hypertonic saline on hospitalization rate in infants with acute bronchiolitis: A meta-analysis [Article]. *Pediatric Pulmonology*, 53(8), 1089-1095. <https://doi.org/10.1002/ppul.24066>

Appendix

Evidence to Decision Assessment for Use of Nebulized 3% Hypertonic Saline

QUESTION

Should nebulized 3% hypertonic saline vs. no nebulized 3% hypertonic saline be used for treatment of hospitalized patients with bronchiolitis?	
POPULATION:	Hospitalized patients with bronchiolitis
INTERVENTION:	Nebulized 3% hypertonic saline
COMPARISON:	No nebulized 3% hypertonic saline
MAIN OUTCOMES:	LOS (hours); LOS (hours) subgroup: High or unclear risk of bias; LOS (hours) subgroup: Risk of bias: Low risk of bias; LOS (hours) subgroup: HS vs SC; LOS (hours) subgroup: HS vs NS; LOS (hours) subgroup: No beta agonist or adrenaline included in nebulization; LOS (hours) subgroup: Beta agonist or adrenaline included in nebulization; LOS (hours) subgroup: Treatment administered every 4 hours; LOS (hours) subgroup: Treatment administered every 6 hours; LOS (hours) subgroup: Treatment administered every 8 hours; LOS (hours): Studies not included in meta-analysis; Wang CSS following 1 day of treatment; Wang CSS following 2 days of treatment; Wang CSS following 3 days of treatment; Need for Supplemental O2; Duration of Supplemental O2 (hours);

ASSESSMENT

Problem Is the problem a priority?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> <input type="radio"/> No <input type="radio"/> Probably no <input type="radio"/> Probably yes <input checked="" type="radio"/> Yes <input type="radio"/> Varies <input type="radio"/> Don't know 	<p>Bronchiolitis is a common illness in patients less than 2 years of age and is one of the most frequent causes of hospital admission for patients less than 12 months of age (Ralston et al., 2014). Mucus production is caused by inflammation of the bronchioles and may result in mucus plugging. Nebulized hypertonic saline (HS) is used to improve mucociliary clearance, though there is currently no direct evidence to show significant improvement (Ralston et al., 2010). The most recent AAP guideline makes a weak recommendation for use in the inpatient setting for patients whose admission exceeds 3 days, however, the average admission for bronchiolitis in the U.S. is 2.4 days (Ralston et al., 2014). This recommendation is based on evidence published prior to 2014.</p>	<p>Increased use of HS treatments increases the number of respiratory therapy (RT) staff needed each shift, while RT is currently experiencing staffing issues.</p>

Desirable Effects How substantial are the desirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Trivial ● Small ○ Moderate ○ Large ○ Varies ○ Don't know 	<p>Length of Stay (LOS) Eleven RCT studies (Everard et al., (2014), Flores-González et al. (2016), Hmar et al., (2021), Islam et al., (2018), Jaquet-Pilloud et al., (2019), Mahesh Kumar et al., (2013), Morikawa et al., (2018), Ojha et al., (2014), Pandit et al., (2013), Sharma et al., (2013), Wu et al., (2014)) reported the mean (SD) LOS, ($n = 1,449$). For the outcome of LOS, the $MD = -6.47$ hours, 95% CI $[-12.72, -0.22]$, $p = .04$, indicated the LOS was shorter for patients that received treatment with 3% HS versus no treatment with 3% HS (see Figure 2 & Table 1).</p> <p>Length of Stay (LOS): Qualitative analysis Alatwani et al. (2021) reported the mean LOS without SD and found a shorter LOS in the group that received treatment with HS (3.38 days) compared to the group that received treatment with nebulized NS (4.67 days), a reduction of 1.3 days (27.8%), $p = .001$. Kose et al. (2016) reported the mean (min – max) LOS and found that the LOS was not different for the groups that received nebulized 3% HS (64 hours), NS (72 hours), or 7% HS (60 hours), $p = .76$. Silver et al., (2015) found that the median (IQR) LOS in days was not different for the group that received nebulized 3% HS (2.1 (1.2 – 4.6)) compared to the group that received nebulized NS (2.1 (1.2 – 3.8)), $p = .73$. Teunissen et al. (2014) reported the median (IQR) LOS in hours and did not find a difference between the group that received nebulized 3% HS (69 (57)), NS (53 (53)), and nebulized 6% HS (70 (69)), $p = .29$.</p> <p>Need for Supplemental Oxygen Four studies (Flores-González et al. (2016), Islam et al., (2018), Ojha et al., (2014), Teunissen et al., (2014)) reported the need for supplemental oxygen ($n = 430$). For the outcome of need for supplemental oxygen, the $OR = 0.88$, 95% CI $[0.57, 1.34]$, $p = .54$, indicating there was no difference between the intervention of treatment with nebulized 3% HS compared to the intervention of no treatment with nebulized 3% HS. (see Figure 10 & Table 1).</p> <p>Duration of Supplemental Oxygen Five studies (Flores-González et al. (2016), Islam et al., (2018), Jaquet-Pilloud et al., (2019), Morikawa et al., (2018), Ojha et al., (2014)) reported the duration of supplemental oxygen in hours ($n = 346$). For the outcome of duration of supplemental oxygen, the $MD = -5.84$, 95%</p>	



	<p>CI [-11.41, -0.28], $p = <.05$, indicating the intervention of treatment with nebulized 3% HS was favorable to the intervention of no treatment with 3% HS.</p> <p>Clinical Severity Scores (CSS) Following 1 Day of Treatment Three studies (Flores-González et al. (2016), Hmar et al., (2021), Kose et al., (2016)) reported the mean (SD) CSS (as described by Wang et al., (1992)) following 1 day of treatment ($n = 296$). For the outcome of improvement of CSS, the $MD = -0.76$, 95% CI [-1.07, -.046], $p = <.05$, indicating the treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 7 & Table 1).</p> <p>Clinical Severity Scores (CSS) Following 2 Days of Treatment Two studies (Flores-González et al. (2016), Hmar et al., (2021)) reported the mean (SD) CSS (as described by Wang et al., (1992)) following 2 days of treatment ($n = 226$). For the outcome of improvement of CSS, the $MD = -0.54$, 95% CI [-0.79, -.028], $p = <.05$, indicating the intervention of treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 8 & Table 1).</p> <p>Clinical Severity Scores (CSS) Following 3 Days of Treatment Two studies (Flores-González et al. (2016), Islam et al., (2018)) reported the mean (SD) CSS (as described by Wang et al., (1992)) following 3 days of treatment ($n = 296$). For the outcome of improvement of CSS, the $MD = -1.19$, 95% CI [-1.67, -.071], $p = <.05$, indicating the treatment with nebulized 3% HS was favorable compared to the intervention of no treatment with 3% HS. (see Figure 9 & Table 1).</p>	
--	---	--

Undesirable Effect How substantial are the undesirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Trivial ○ Small ● Moderate ○ Large ○ Varies ○ Don't know 	<p>Adverse events include bronchospasm, increased coughing, tachycardia, apnea, infection, cyanosis, and tremor. Seven studies reported adverse events ($N = 1436$). There was no difference in the number of adverse events between the patients treated with 3% HS compared to the group not treated with 3% HS, OR = 1.1, 95% CI [0.59, 2.05], $p = .76$.</p>	<p>Treatments with HS incur cost to the hospital and patient through medication cost and staff time to administer treatment.</p> <p>Patients may experience distress or discomfort during treatment</p> <p>Misrepresentation of the benefits of treatment to patients' families may lead to requests for nebulizers and treatment at home after discharge.</p> <p>Use of HS treatments may drive use of other overutilized treatments such as albuterol</p>
Certainty of evidence What is the overall certainty of the evidence of effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ● Very low ○ Low ○ Moderate ○ High ○ No included studies 	<p>Overall certainty of the evidence is very low due to serious risk of bias (lack of or unclear description of blinding of study personnel), serious indirectness (use of beta agonist/adrenaline in some studies, frequency/timing of treatment, use of NS or standard care as control), and serious imprecision (wide confidence interval).</p>	

Values Is there important uncertainty about or variability in how much people value the main outcomes?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Important uncertainty or variability ● Possibly important uncertainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability 		<p>There is possible variation in the value placed on length of stay, cost of treatment, staff usage to administer treatment, and value placed on treatment by patients' families.</p> <p>The definition of clinically significant differences in length of stay is uncertain.</p>
Balance of effects Does the balance between desirable and undesirable effects favor the intervention or the comparison?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ● Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ○ Favors the intervention ○ Varies ○ Don't know 	<p>The evidence shows a shorter length of stay for patients receiving treatment with HS versus patients not receiving treatment with HS, but shows no difference for need for oxygen supplementation, duration of oxygen supplementation, or clinical severity scores following treatment.</p>	<p>Treatment with HS may increase cost to the patient and hospital, use of hospital staff, and patient discomfort without necessarily improving the care of the patient with routine bronchiolitis.</p> <p>The shorter length of stay for patients receiving treatment with HS was not deemed likely to be clinically significant when considering the range of the CI.</p>

Resources required How large are the resource requirements (costs)?"		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Large costs ● Moderate costs ○ Negligible costs and savings ○ Moderate savings ○ Large savings ○ Varies ○ Don't know 		The resources required for the intervention (HS) includes the cost to the patient for treatment (\$218 charge for RT visit plus medication charges), cost of RT time (estimated to be wages of \$36/hour and 30 minutes per treatment), and use of hospital staff to administer treatment.
Certainty of evidence of required resources What is the certainty of the evidence of resource requirements (costs)?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Very low ○ Low ● Moderate ○ High ○ No included studies 	The average length of stay for hospitalized patients with bronchiolitis in the U.S. is 2.4 days (Ralston et al., 2014) and the geometric mean of direct cost of hospitalization in 2016 in the US was \$3724, 95% CI [3572, 3876] for patients with primary diagnosis of bronchiolitis without other complex chronic conditions (Fujiogi et al., 2019).	Evidence exists for cost of length of stay for bronchiolitis but not for direct cost of HS treatment. Resource costs provided by CMH.
Cost effectiveness Does the cost-effectiveness of the intervention favor the intervention or the comparison?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Favors the comparison ● Probably favors the comparison ○ Does not favor either the intervention or the comparison ○ Probably favors the intervention ○ Favors the intervention ○ Varies ○ No included studies 		The cost of resources for treatment with HS is likely higher than a minimal reduction in length of stay.

Equity What would be the impact on health equity?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ Reduced ○ Probably reduced ○ Probably no impact ○ Probably increased ○ Increased ○ Varies ● Don't know 		<p>No evidence found to address inequities with treatment with HS.</p> <p>Inequities exist for effect of increased/decreased length of stay for those experiencing barriers related to transportation, healthcare access, health literacy and other social determinants of health.</p> <p>Inequities exist for effect of treatment cost on those with lower income.</p>
Acceptability Is the intervention acceptable to key stakeholders?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> ○ No ○ Probably no ○ Probably yes ○ Yes ● Varies ○ Don't know 		<p>Variation of acceptability exists for providers and respiratory therapists when administering treatment that may not have evidence-based benefits.</p>

Feasibility Is the intervention feasible to implement?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
<ul style="list-style-type: none"> <input type="radio"/> No <input type="radio"/> Probably no <input checked="" type="radio"/> Probably yes <input type="radio"/> Yes <input type="radio"/> Varies <input type="radio"/> Don't know 		<p>Feasibility may be affected by staffing availability to administer treatments, patients experiencing distress and parent dissatisfaction.</p> <p>Supplies needed for treatment are generally readily available with infrequent supply unavailability.</p>

Evidence Based Practice

SUMMARY OF JUDGEMENTS

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Very low	Low	Moderate	High			No included studies
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	No included studies
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

JUDGEMENT							
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know

TYPE OF RECOMMENDATION

Strong recommendation against the intervention ○	Conditional recommendation against the intervention ●	Conditional recommendation for either the intervention or the comparison ○	Conditional recommendation for the intervention ○	Strong recommendation for the intervention ○
---	---	---	--	---